

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Welcome to STN International! Enter x:x

LOGINID: ssspta1600rxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 Apr 08 "Ask CAS" for self-help around the clock
NEWS 3 Apr 09 BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 Apr 09 ZDB will be removed from STN
NEWS 5 Apr 19 US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6 Apr 22 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 Apr 22 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Apr 22 Federal Research in Progress (FEDRIP) now available
NEWS 9 Jun 03 New e-mail delivery for search results now available
NEWS 10 Jun 10 MEDLINE Reload
NEWS 11 Jun 10 PCTFULL has been reloaded
NEWS 12 Jul 02 FOREGE no longer contains STANDARDS file segment
NEWS 13 Jul 22 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
NEWS 14 Jul 29 Enhanced polymer searching in REGISTRY
NEWS 15 Jul 30 NETFIRST to be removed from STN
NEWS 16 Aug 08 CANCERLIT reload
NEWS 17 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18 Aug 08 NTIS has been reloaded and enhanced
NEWS 19 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 20 Aug 19 IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21 Aug 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 23 Sep 03 JAPIO has been reloaded and enhanced
NEWS 24 Sep 16 Experimental properties added to the REGISTRY file
NEWS 25 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 26 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 27 Oct 21 EVENTLINE has been reloaded
NEWS 28 Oct 24 BEILSTEIN adds new search fields
NEWS 29 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 30 Oct 25 MEDLINE SDI run of October 8, 2002
NEWS 31 Nov 18 DKLILIT has been renamed APOLLIT
NEWS 32 Nov 25 More calculated properties added to REGISTRY
NEWS 33 Dec 02 TIBKAT will be removed from STN
NEWS 34 Dec 04 CSA files on STN
NEWS 35 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 36 Dec 17 TOXCENTER enhanced with additional content
NEWS 37 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 38 Dec 30 ISMEC no longer available
NEWS 39 Jan 13 Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 40 Jan 21 NUTRACEUT offering one free connect hour in February 2003
NEWS 41 Jan 21 PHARMAML offering one free connect hour in February 2003
NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b (ENG) AND V6.0b (JP)

NEWS HOURS AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS INTER STN Operating Hours Plus Help Desk Availability
NEWS LOGIN General Internet Information
NEWS PHONE Welcome Banner and News Items
NEWS WWW Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 07:01:50 ON 03 FEB 2003

FILE 'REGISTRY' ENTERED AT 07:02:00 ON 03 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 31 JAN 2003 HIGHEST RN 484598-30-3
DICTIONARY FILE UPDATES: 31 JAN 2003 HIGHEST RN 484598-30-3

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.


Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>
Uploading 09815362.str

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 07:02:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2113 TO ITERATE

47.3% PROCESSED 1000 ITERATIONS 9 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 39504 TO 45016
PROJECTED ANSWERS: 119 TO 641

L2 9 SEA SSS SAM L1

=> s l1 full
FULL SEARCH INITIATED 07:02:17 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 41513 TO ITERATE

100.0% PROCESSED 41513 ITERATIONS 417 ANSWERS
SEARCH TIME: 00.00.01

L3 417 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	148.15	148.36

FILE 'CAPLUS' ENTERED AT 07:02:22 ON 03 FEB 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Feb 2003 VOL 138 ISS 6
FILE LAST UPDATED: 2 Feb 2003 (20030202/ED)


This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l3
L4          33 L3
=> d ibib abs hitstr 1-33
```

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:154359 CAPLUS
 DOCUMENT NUMBER: 137:263032
 TITLE: Preparation of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors
 INVENTOR(S): Chow, Ken; Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.; Gomez, Dario G.
 PATENT ASSIGNEE(S): Allergan, Inc., USA
 SOURCE: PCT Int. Appl., 141 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE		
WO 2002076950	A2	20021003	WO 2002-US8222	20020313		
W: AE, AG, AL, AM, AT, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZN, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM	W: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BV, CF, CG, CI, CH, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG	US 2003023098	A1	20030130	US 2001-815362	A 20010321
PRIORITY APPLN. INFO.:			US 1997-985347	B2	19971204	
			US 1998-205597	B2	19981204	
			US 1999-329752	B2	19990610	

OTHER SOURCE(S): MARPAT 137:26302
 GI



AB Compds. (shown as I), which are selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors and useful for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects, are claimed. Also included are methods of making and using such compds. In I, each x is independently 1 or 2; each R1 is independently H, Cl-4 alkyl or Cl-4 alkyl(Cl-4 alkyl); Cl-4 alkenyl; -CON where R is H, Cl-4 alkyl or Cl-4 alkoxy; Cl-6 cycloalkyl; aryl-heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5) where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or Hl-2. Each R2 and each R3 are


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 independently H; Cl-4 alkyl; Cl-4 alkenyl; Cl-4 alkylnyl; -COR4 where R4 is H, Cl-4 alkyl or Cl-4 alkoxy; Cl-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl; oxo; or -(CH2)n-X-(CH2)m-(R5) where X is O, S or N, n is 0-3, m is 0-3, o is 0-1, and R5 is Me or Hl-2; or an R2 and an R3 together condense to form a satd., partly satd., or unsatd. ring structure having the formula -[C(R6)p]q-Xs-[C(R6)p]r-Kt-[C(R6)p]u where each R6 is independently H; halogen; Cl-4 alkyl; Cl-4 alkenyl; Cl-4 alkylnyl; -COR4 where R4 is H, Cl-4 alkyl or Cl-4 alkoxy; Cl-6 cycloalkyl; aryl; heteroaryl; cyano; nitro; trihalomethyl and oxo where each p is independently 1 or 2, q is 0-5, r is 0-5, u is 0-5. Each X is independently O, S, or N and s is 0 or 1; provided that q + p + s + t < 6. Y is O, S, N, -[C(R7)2]3-, Where each R7 is independently a CH, -CH2- or -CH= where Y1 is O, S, or N; or -S- where the dotted lines in I are optional double bonds with the proviso that if the ring including Y is a cyclohexane ring or a heterocyclic 5 member ring said ring is not fully unsatd., and that if Y is O, N or S, the ring including Y contains at least one said double bond. Intrinsic activities towards .alpha.2A, .alpha.2B, .alpha.2C adrenergic receptors of .apprx.100 of the claimed compds. related to brimonidine/oxymetazoline are tabulated. Although the methods of prepn. are not claimed, .apprx.100 example prepns. are included.

IT 157058-47-4P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
 RL: US (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(prepn. of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors)

RN 157058-47-4 CAPLUS

1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-(9CI) (CA INDEX NAME)




IT 157058-44-1P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- 157058-52-1P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 157058-53-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- 226570-47-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride 226571-02-4P, 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- 226570-05-7P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-12-7P, 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-14-8P, 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- 226571-25-1P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- 226571-26-2P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- 226571-35-3P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-dimethyl-2-naphthalenyl)methyl]-


L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 226571-36-4P, 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-, monohydrochloride 226571-37-5P, 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of imidazoles as selective agonists at .alpha.2B or .alpha.2B/.alpha.2C adrenergic receptors)

RN 157058-44-1 CAPLUS


1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-02-4 CAPLUS

L4 ANSWER 1 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-26-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)




RN 226571-35-3 CAPLUS
CN 1H-imidazole, 4-((1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl)- (9CI) (CA INDEX NAME)



RN 226571-36-4 CAPLUS
CN 1H-imidazole, 4-((1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl)-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl
RN 226571-37-5 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)




IT 226571-57-8P, 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)
RN: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 226571-57-9 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
ACCESSION NUMBER: 2002:576071 CAPLUS
DOCUMENT NUMBER: 137:262610
TITLE: Highly Enantioselective Reformatskii Reaction of Ketones: Chelation-Assisted Enantioface Discrimination
AUTHOR(S): Ojida, Akio; Yamano, Toru; Taya, Nachiro; Tasaka, Akira
CORPORATE SOURCE: Medicinal Chemistry Research Laboratories, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan
SOURCE: Organic Letters (2002) 4(18), 3051-3054
CODEN: ORLEFT; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Highly enantioselective Reformatskii reaction of ketones was accomplished using cinchona alkaloids as chiral ligands. Chelation with the sp²-nitrogen adjacent to the reactive carbonyl center contributed to the enantioface discrimination for the high enantioselectivities.
IT 463304-60-1
RN: RCT (Reactant); RACT (Reactant or reagent); (chelation-assisted enantioface discrimination in asym. Reformatskii reaction)
CN 463304-60-1 CAPLUS
Methanand 2-naphthalenyl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



IT 463304-61-2P 463304-63-4P 463304-73-6P
463304-74-7P
RN: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (chelation-assisted enantioface discrimination in asym. Reformatskii reaction)
CN 463304-61-2 CAPLUS
1H-Imidazole-4-propanoic acid, .beta.-hydroxy-.beta.-2-naphthalenyl-1-(triphenylmethyl)-, 1,1-dimethylethyl ester, (.beta;.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 463304-63-4 CAPLUS


L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN 2-Oxazolidinone, 3-((3S)-3-hydroxy-3-(1H-imidazol-4-yl)-3-(2-naphthalenyl)-1-oxopropyl)-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 463304-73-6 CAPLUS
CN 1,3-Propanediol, 1-(2-naphthalenyl)-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-, (1S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 463304-74-7 CAPLUS
CN 2-Oxazolidinone, 3-((3S)-3-hydroxy-3-(2-naphthalenyl)-1-oxo-3-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl)-4-phenyl-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 463304-82-3P
RN: SPN (Synthetic preparation); PREP (Preparation); (chelation-assisted enantioface discrimination in asym. Reformatskii reaction)
CN 463304-62-3 CAPLUS
1,3-Propanediol, 1-(1H-imidazol-4-yl)-1-(2-naphthalenyl)-, (1S)- (9CI)

L4 ANSWER 2 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2002:391718 CAPLUS
DOCUMENT NUMBER: 136:386117
TITLE: Preparation of 7-aryldihydropyrrrolo[1,2-c]imidazol-7-ols and analogs as steroid 17-20-lyase inhibitors
INVENTOR(S): Tasaka, Akihiro; Hitaka, Takenori; Matsumaga, Nobuyuki; Kusaka, Masami; Adachi, Mari; Aoki, Isao; Ojida, Akio
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 92 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040484	A2	20020523	WO 2001-JP10002	20011116
WO 2002040484	A3	20020926		
		W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AH, A2, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, 2M, 2W, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CF, CO, CL, CR, GA, GN, GW, HU, MR, NE, SI, TD, TG		
AU 2002014296	A5	20020527		
		PRIORITY APPLN. INFO.: JP 2000-351780 A 20001117		
		JP 2001-247618 A 20010817		
		JP 2001-336980 A 20011101		
		WO 2001-JP10002 W 20011116		

OTHER SOURCE(S): MARPAT 136:386117

GI




AB Title compds. [I; R = (un)substituted aryl; Z = (CH2)1-3] were prep'd. The 1-trityl-1H-imidazole-4-carboxaldehyde was condensed with MeCO2Et in the presence of BuLi and the product converted in 2 steps to HOCH2CH2CHO (R1 = 1-trityl-1H-imidazole-4-yl) which was cyclized to give 5,6-dihydro-7H-pyrrrolo[1,2-c]imidazol-7-one. The latter was arylated by 5-methoxybenzo[b]thiophene to give I [R = 5-methoxybenzo[b]thiophen-2-yl, Z = CH2]. Data for biol. activity of I were given.

IT 426219-47-8P 426219-55-8P 426219-56-9P


426219-58-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
steroid 17-20-lyase inhibitors
RN 426219-47-8 CAPLUS
CN 2-Naphthalenecarboxamide, N,N-bis(1-methylethyl)-6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)



RN 426219-55-8 CAPLUS
CN 1H-imidazole-4-propanoic acid, .beta.-[6-[(bis(1-methylethyl)amino)carbonyl]-2-naphthalenyl]-.beta.-hydroxy-1-(triphenylmethyl)- ethyl ester (9CI) (CA INDEX NAME)




RN 426219-56-9 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1,3-dihydroxy-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 426219-58-1 CAPLUS
CN 1H-Imidazole-4-propanoic acid, .beta.-[6-[(bis(1-methylethyl)amino)carbonyl]-2-naphthalenyl]-.beta.-hydroxy-1-(triphenylmethyl)-, 1,1-dimethylethyl ester, (.beta.,S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 3 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2002:391704 CAPLUS
 DOCUMENT NUMBER: 136:401756
 TITLE: Preparation of imidazole derivatives for treatment of prostate and breast cancer
 INVENTOR(S): Tasaka, Akihiro; Matsunaga, Nobuyuki; Ojida, Akio; Kusaka, Masami
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 81 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040470	A1	20020523	W 2001-3P10079	20011119
W: AS, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HB, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
AU 200214320	A5	20020527	AU 2002-14320	20011119
JP 2002241377	A2	20020828	JP 2001-353524	20011119
JP 2000-353634 A 20001120				
JP 2000-382056 A 20001215				
WO 2001-JP10079 W 20011119				


PRIORITY APPLN. INFO.:

OTHER SOURCE(S): MARPAT 136:401756
 GI




AB The title compds., e.g. I [R is hydrogen or a protecting group; R1 is lower alkyl or cycloalkyl; and ring A is an optionally substituted 5- or 6-membered ring having an amide linkage], are prep'd. as steroid C17-20 lyase inhibitors and are useful in the treatment of prostate and breast cancer. The process for prep'd. is disclosed. 7-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1,2-dihydro-3H-benz[e]isoindol-3-one inhibited the biosynthesis of testosterone in rats. Formulations are given.

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 IT 430472-50-7P
 RL: IMP (Industrial manufacture); PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (prep. of imidazole derivs. for treatment of prostate and breast cancer)
 RN 430472-50-7 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-2-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 430472-30-3P 430472-32-5P 430472-34-7P
 430472-38-1P 430472-39-2P
 430472-40-5P 430472-41-6P 430472-42-7P
 430472-43-8P 430472-44-9P 430472-45-0P
 430472-46-1P 430472-47-2P 430472-48-3P
 430472-49-4P 430472-51-5P 430472-52-6P
 430472-53-0P
 RL: IMP (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of imidazole derivs. for treatment of prostate and breast cancer)
 RN 430472-30-3 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-32-5 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 430472-34-7 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-ethyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 430472-36-9 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-propyl- (9CI) (CA INDEX NAME)




RN 430472-38-1 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 430472-39-2 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-cyclopropyl-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 4 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 430472-40-5 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-(2,2,2-trifluoroethyl)- (9CI) (CA INDEX NAME)




RN 430472-41-6 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 2-(dimethylamino)-1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-42-7 CAPLUS
 CN Benzo[f]phthalazin-4(1H)-one, 2,3-dihydro-8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-43-8 CAPLUS
 CN Benzo[f]phthalazin-4(3H)-one, 8-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-44-9 CAPLUS
 CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-45-0 CAPLUS
 CN 1H-Benz[f]isoindol-1-one, 2,3-dihydro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-46-1 CAPLUS
 CN Benzo[g]phthalazin-1(2H)-one, 3,4-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 430472-47-2 CAPLUS
 CN Benzo[g]phthalazin-1(2H)-one, 7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-



RN 430472-48-3 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-49-4 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 430472-51-8 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-methyl-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).



RN 430472-52-9 CAPLUS
 CN 1H-Imidazole-1-carboxylic acid, 4-[1-(2,3-dihydro-2-methyl-3-oxo-1H-benz[e]isoindol-7-yl)-1-hydroxy-2-methylpropyl]-, 2-propenyl ester (9CI) (CA INDEX NAME)




RN 430472-53-0 CAPLUS
 CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-2-methyl- (9CI) (CA INDEX NAME)




IT 247173-85-9 247174-16-9 337520-93-1
 337521-09-2 337521-12-7 337521-14-9
 337521-16-1 337521-18-3 337521-22-9
 337521-24-1 337521-26-3 337521-83-2
 430472-54-1 430472-55-2 430472-56-3
 430472-57-4 430472-58-5 430472-59-6
 430472-60-9 430472-61-0 430472-62-1
 430472-63-2 430472-64-3 430472-69-8
 430472-70-1 430472-71-2 430472-73-4
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of imidazole derivs. for treatment of prostate and breast
 cancer)


RN 247173-85-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[(6-hydroxy-2-naphthalenyl)-.alpha.-[(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-16-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[(6-[(1,1-dimethylethyl)dimethylsilyl]oxy-2-naphthalenyl)-.alpha.-[(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337520-93-1 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-2-naphthalenyl]propyl]- (9CI) (CA INDEX NAME)




RN 337521-09-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[(6-[(1,1-dimethylethyl)dimethylsilyl]oxy-5-methyl-2-naphthalenyl)-.alpha.-[(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-12-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[(6-hydroxy-5-methyl-2-naphthalenyl)-.alpha.-[(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-14-9 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-16-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-18-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-7-methyl-2-naphthalenyl-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-22-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-hydroxy-7-methyl-2-naphthalenyl]-




RN 337521-24-1 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-26-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-3-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-83-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-54-1 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-(bromomethyl)-6-[1-hydroxy-2-methyl-1-[1-




RN 430472-55-2 CAPLUS
CN 2-Naphthalenecarboxylic acid, 3-(bromomethyl)-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-56-3 CAPLUS
CN Methanone, [6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 430472-57-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-5-methyl-2-naphthalenyl[1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 430472-58-5 CAPLUS
CN Methanone, (6-hydroxy-5-methyl-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 430472-59-6 CAPLUS
CN Methanesulfonic acid, trifluoro-, 1-methyl-6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 430472-60-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-methyl-6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-61-0 CAPLUS
CN 2-Naphthalenecarboxylic acid, 1-(bromomethyl)-6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 430472-62-1 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-2-methyl-7-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 430472-63-2 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 430472-64-3 CAPLUS
CN 2-Naphthalene carboxamide, 1-formyl-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 430472-69-8 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 430472-70-1 CAPLUS



RN 430472-71-2 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-[(methylamino)methyl]-N,N-bis(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 430472-73-4 CAPLUS
CN 3H-Benz[e]isoindol-3-one, 1,2-dihydro-7-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


ACCESSION NUMBER: 2002-353314 CAPLUS
DOCUMENT NUMBER: 136:365878
TITLE: Methods and compositions for treatment of ocular neovascularization and neural injury
INVENTOR(S): Burke, James A.; Lin, Ton; Wheeler, Larry A.; De Vries, Gerald W.
PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002036162	A2	20020510	WO 2001-US46014	20011101
W: AE, AG, AL, AM, AU, A2, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, C2, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, A2, BY, KG, KZ, MD, RU, TJ, TM, RW: GE, HN, KE, LS, RW, MZ, SD, SL, S2, T2, AG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, CH, CY, DE, DK, ES, FI, FR, GR, IE, IT, LU, MC, NL, PT, SE, TR, AU: 2002-30567	20011101			
AU 2002030567	A5	20020515	US 2001-398778	20011101
US 2002094998	A1	20020718	US 2000-244850P	20001101
PRIORITY APPLN. INFO.:			WO 2001-US46014	W 20011101


AB Methods and compns. for the treatment of ocular neovascularization (CNV) and macular degeneration are disclosed. The invention includes combining laser treatment with administration of a neuroprotectant. Seven pigmented rabbits were dosed with either 0.5 ml 0.2% brimonidine or saline administered in 1 eye of each rabbit. One hour later, the animals were treated with a 10-min i.v. infusion of 0.2 mg/kg verteporfin, then the same eye was irradiated 10 min later in the lower fundus with a 689-nm diode laser at 50 J/cm², 600 mW/cm² and a spot size of 1.5 mm. Brimonidine reduced the increase in retinal thickness (subretinal cyst + retinal) in the lesion produced by PDT.

IT 226571-05-7, AGR 795 200103-40-4, AGR 960
RE: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological activity); USES (Uses);
(methods and compns. for treatment of ocular neovascularization and neural injury)

RN 226571-05-7 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 423773-40-4 CAPLUS
CN 1(2H)-Naphthalene, 2-[(2,3-dihydro-2-thioxo-1H-imidazol-4-yl)methyl]-3,4-dihydro- (9CI) (CA INDEX NAME)



14 ANSWER 6 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001-84687 CAPLUS
DOCUMENT NUMBER: 136:146987
TITLE: Investigations on inhibitors of human
17, alpha.-hydroxylase-17,20-lyase and their
interactions with the enzyme. Molecular modelling of
17, alpha.-hydroxylase-17,20-lyase, part II
AUTHOR(S): Schappach, A.; Holtje, H.-D.
CORPORATE SOURCE: Department of Pharmacy, Institute of Pharmaceutical
Chemistry, Heinrich Heine-University, Dusseldorf,
Germany
SOURCE: Pharmazie (2001), 56(11), 835-842
PUBLISHER: Goovi-Verlag Pharmazeutischer Verlag
DOCUMENT TYPE: Journal Article
LANGUAGE: English
AB New methods in treatment of hormone-dependent diseases like prostate or breast cancer have become a major subject in medical and pharmaceutical research. Because of the direct correlation of cancer growth and hormone concn., inhibition of hormone biosynthesis presents a promising strategy in cancer therapy. The key enzyme in androgen biosynthesis is the 17, alpha.-hydroxylase-17,20-lyase a cytochrome P 450 system, which specifically converts pregnenolone to androgens. Because the 3D-structure of the enzyme is still unknown most recently a ligand-based design was used to gain deeper insights into protein structure and function. In this paper we present mol. modeling studies on compds. acting as competitive inhibitors of the human 17, alpha.-hydroxylase-17,20-lyase. The compds. developed by Hartmann et al. belong to two different structural classes and show a wide range of inhibitory potency. The physico-chem. properties of the molis. were investigated and compared by studying structural flexibility and by calcg. mol. interactions fields. The superimposition of all inhibitors in a low energy conformation yielded in the common pharmacophore. In the second part of the paper individual inhibitors were docked into the active site of the 17, alpha.-hydroxylase of CYP17 developed in our group. The dynamic behavior and stability of the protein-inhibitor complexes was studied. The protein ligand interactions obmd. in course of the mol. dynamics simulations correspond well with the exptl. data.
15 157058-47-1

IT 157058-47-
RL (Physical properties)
(enz. modeling of human 17.alpha.-hydroxylase-17,20-lyase with
steroidal and non-steroidal inhibitors)
RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-
(9CI) (CA INDEX NAME)




REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

14 ANSWER 7 OF 33 CAPTUS COPYRIGHT 2003 ACS. (Continued)
 The optically active isomer produced has a steroid C17,20 lyase inhibitory activity and is useful as a preventive/remedy for tumors such as prostatic and mammary cancer. Also provided is a novel optical resolver II or III. Thus, 1.0 g (RS)-1-(6,7-dimethoxyphenyl-2-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol (IV) (prep., given) and 822 mg (−)-8-hydroxy-7,9-dioxa-6-phenyl-8-phosphoquinuclidine-4(5)-decan-8-one (V) were dissolved in 21 mL ethanol with heating, stirred at room temp. for 6 h, and filtered to give 670 mg (−)-IV·V salt (99% de) in 74% yield which (665 mg) was added to 150 mg 251 ap. NH₃, 30 mL H₂O, and 20 mL AcOEt, and stirred at room temp. for 30 min. The org. layer was sepd. and concd. in vacuo to give 368 mg (−)-IV (99% de) in 74% yield.


IT 336102-59-7 336102-62-6P
 RU PUP (Purification or preparation); SPP (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphorophinanone resolving agents)
 RN 336102-55-7 CAPIUS
 CN 1H-Imidazole-4-methanol, α -[(6,7-dimethoxy-2-naphthalenyl)- α -methyl-1-methyl-1H-[(alpha,S)- (SC1) [CA INDEX NAME]

Absolute stereochemistry. Rotation (-).



RN 336102-62-6 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-.beta.-(9CI) (CA INDEX NAME)

Rotation (-)



48 - CADASTRO 00-5-000100-01-0-000100-00-0

IT 247174-36-8 336102-65-9 336102-70-6
 336102-73-9
 RU: (reactant); RACT (Reactant or reagent)
 (process for producing optically active anticancer naphthalene deriv.
 and hydroxycinnamylidene phosphoranimine resolving agents)
 CN 247174-39-6 CAPLUS
 1H-Imidazole-4-methanol, α -[(diphenylmethylene)amino]-2-
 naphthalenyl- α -(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA
 INDEX NAME)


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 2001:319877 CAPLUS
DOCUMENT NUMBER: 134:340525
TITLE: Process for producing optically active naphthalene
derivative and optical resolver therefor
INVENTOR(S): Aoki, Iwao; Adachi, Mari; Kawada, Mitsuuru; Yamano,
Toru; Taya, Naohiro
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 103 pp.
CODEN: PIXKD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT INFORMATION:		KIND	DATE	APPLICATION NO.	DATE
PATENT NO.:		AI	20010503	WO 2000-JP7282	20001019
WO 2001030763		AI	20010503	WO 2000-JP7282	20001019
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, LA, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GE, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CL, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, CF, CG, CI, GM, GA, GN, GW, ML, MR, NE, SM, TD, TG				
AU 2000079499	A5	20010508	AU 2000-79499	20001019	
EP 1227085	AL	20020731	EP 2000-96902	20001019	
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PL, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2001187785	A2	20010710	JP 2000-320499	20001020	
PRIORITY APPLN. INFO.:			JP 1999-301570	A	19991022
			JP 1999-301576	A	19991022
			WO 2000-JP7282	W	20001019
OTHER SOURCE(S):		MARPAT 134:340525			


STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY. AVAILABLE VIA OFFLINE PRINT.

AB A process for producing an optically active isomer of a compd. represented by formula (I) which comprises: reacting a mixt. of naphthalene derivs. represented by formula I (wherein R represents a nitrogenous heterocyclic group; R1 represents hydrogen, a hydrocarbon group, or a monocyclic aram. heterocyclic group; R2 represents hydrogen or lower alkyl; symbol indicates the position of an asym. carbon atom) and R3 to R8 each represents hydrogen, a hydrocarbon group, hydroxy, etc., provided that R7 may be bonded to R6 or R8 to form a ring contg. an oxygen atom) with an optically active isomer of 2-hydroxy-4-phenyl-1,3,2-dioxaphosphorinan-2-one or aram. ring-fused 2-hydroxy-1,3,2-dioxaphosphorinan-2-one compd. represented by formula (II) or (III), resp. (wherein ring A represents a benzene ring; R10 and R11 each represents hydrogen, a hydrocarbon group, etc. or R10 and R11 in combination represent alkylene; symbol indicates the position of an asym. carbon atom) and rings B and C each represents an aram. ring) to yield salts; sepg. the salts; and then isolating the target an


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 336102-65-9 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-{1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl}-, methyl ester (9CI) (CA INDEX NAME)



RN 336102-70-6 CAPLUS
CN 2-Naphthaleneacboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-
N-methyl- (9CI) (CA INDEX NAME)




RN 336102-73-9 CAPLUS
CN 2-Naphthalene-carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




IT	247173-05-3P	247173-20-2P	247173-40-6P
	247173-41-7P	247173-54-2P	247173-70-2P
	247173-71-3P	247173-72-4P	247174-10-3P
	247174-11-4P	247174-12-5P	247174-40-9P
	247174-41-0P	247174-69-5P	336102-57-5P
	336102-59-5P	336102-61-5P	336102-73-1P
	336102-66-8P	336102-74-9P	336102-77-7P
	336102-69-5P	336102-75-9P	336102-79-9P
	336102-78-5P	336102-78-9P	


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 337534-07-3P 337534-08-4P 337534-10-8P
 337534-11-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (process for producing optically active anticancer naphthalene deriv.
 and hydroxyphenyldioxaphosphorinane resolving agents)
 RN 247173-05-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)



RN 247173-40-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS
 CN Acetamide, N-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-70-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247173-71-3 CAPLUS
 CN Methanone, (6-methoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 247173-72-4 CAPLUS
 CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247174-10-3 CAPLUS
 CN Methanone, 1H-imidazol-4-yl(6-ethoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-11-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS
 CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-40-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS
 CN Acetamide, N-[6-(1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247174-69-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 336102-57-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (.alpha.S)-, compd. with (-)-8-hydroxy-6-phenyl-7,9-dioxa-8-phosphaspiro[4.5]decane 8-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-56-8

CMF C19 H22 N2 O3

Rotation (-).




CH 2

CRN 336102-55-7

CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



RN 336102-59-1 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2,4-dichlorophenyl)-2-hydroxy-5-diethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 336102-58-0

CMF C19 H22 N2 O2

14 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Rotation (-).



CH 2

CRN 98674-91-0
CNF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (-).




RN 336102-61-5 CAPLUS

CN Acetamide, N-(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl)-, (+)-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-60-4
CNF C19 H21 N3 O2

Rotation (+).




CH 2

CRN 98674-82-9
CNF C12 H17 O5 P

14 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

Absolute stereochemistry. Rotation (+).




RN 336102-63-7 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (-)-4-(4-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-62-6
CNF C18 H20 N2 O2


Rotation (-).



CH 2

CRN 98674-89-6
CNF C11 H14 Cl O4 P

Rotation (-).



RN 336102-64-8 CAPLUS


CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-

14 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
methylethyl)-, (-)-, compd. with (4S)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-62-6
CNF C18 H20 N2 O2


Rotation (-).




CH 2

CRN 98674-83-0
CNF C12 H17 O5 P

Absolute stereochemistry. Rotation (-).

RN 336102-66-0 CAPLUS
CN 2-Naphthalene carboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 336102-65-9
CNF C20 H22 N2 O3

CH 2


14 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CRN 98674-87-4
CNF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (+).

RN 336102-67-1 CAPLUS
CN 2-Naphthalene carboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-, methyl ester, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CH 1

CRN 336102-65-9
CNF C20 H22 N2 O3

CH 2

CRN 98674-90-9
CNF C11 H13 Cl2 O4 P


Absolute stereochemistry. Rotation (+).

RN 336102-69-3 CAPLUS
CN 2-Naphthalene carboxylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester, compd. with (4S)-4-(2-chlorophenyl)-2-

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 336102-68-2
 CMF C19 H20 N2 O3



CH 2

CRN 98674-86-3
 CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (-).



RN 336102-71-7 CAPLUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-70-6
 CMF C20 H23 N3 O2




L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CH 2

CRN 98674-87-4
 CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-72-8 CAPLUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (-)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-70-6
 CMF C20 H23 N3 O2




CH 2

CRN 98674-91-0
 CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (-).


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 336102-74-0 CAPLUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-4-(2,4-dichlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1


CRN 336102-73-9
 CMF C18 H19 N3 O2



CH 2

CRN 98674-90-9
 CMF C11 H13 Cl2 O4 P

Absolute stereochemistry. Rotation (+).




RN 336102-75-1 CAPLUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-73-9
 CMF C18 H19 N3 O2


L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CH 2

CRN 98674-87-4
 CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).



RN 336102-76-2 CAPLUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (+)-2-hydroxy-4-(2-methoxyphenyl)-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-73-9
 CMF C18 H19 N3 O2




CH 2

CRN 98674-82-9
 CMF C12 H17 O5 P

Absolute stereochemistry. Rotation (+).

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337534-07-3 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (11bR)-4-hydroxydiphospho(2,1-d:1',2'-f)(1,3,2)dioxaphosphorinane 4-oxide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).



CM 2

CRN 39648-67-4
CMF C20 H13 O4 P


RN 337534-08-4 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-4-phenyl-

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2

CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-11-9 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 336102-62-6
CMF C19 H20 N2 O2

Rotation (-).

CM 2
CRN 98674-86-3
CMF C11 H14 Cl O4 P

Absolute stereochemistry. Rotation (-).




IT 336103-01-6P 336103-02-7P 336103-04-9P

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336102-55-7
CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).



CM 2

CRN 98674-80-7
CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).




RN 337534-10-8 CAPLUS

CN 1H-imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl-, (-)-, compd. with (4S)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 337534-09-5
CMF C18 H20 N2 O2

Rotation (-).



L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

336103-05-1P 337534-12-0P
RL: SPN (Synthetic Preparation); PREP (Preparation)
(processes for producing optically active anticancer naphthalene deriv. and hydroxyphenyldioxaphosphorinane resolving agents)


RN 336103-01-6 CAPLUS

CN Cyclohexanecarboxylic acid, 2-(aminocarbonyl)-, (1S,2R)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)


CM 1

CRN 336103-00-5
CMF C8 H13 N O3

Absolute stereochemistry.




CM 2

CRN 247173-41-7
CMF C19 H22 N2 O3

RN 336103-02-7 CAPLUS
 CN Benzenoacetic acid, .alpha.-hydroxy-, (.alpha.S)-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-41-7
CMF C19 H22 N2 O3

CM 2

CRN 17199-29-0

L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CMF C8 H8 O3

Absolute stereochemistry. Rotation (+).


RN 336103-04-9 CAPLUS
CN 2-Naphthalene carboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 336103-03-8

CMF C18 H19 N3 O2

Absolute stereochemistry. Rotation (-).




CM 2

CRN 98674-87-4

CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).

RN 336103-06-1 CAPLUS
CN 2-Naphthalene carboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-, compd. with (4R)-4-(2-chlorophenyl)-2-hydroxy-5,5-dimethyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)L4 ANSWER 7 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CM 1

CRN 336103-05-0

CMF C20 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 98674-87-4

CMF C11 H14 Cl O4 P


Absolute stereochemistry. Rotation (+).

RN 337534-12-0 CAPLUS
CN Sulfamic acid, [(1S)-1-phenylethyl]-, compd. with .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1H-imidazole-4-methanol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 247173-41-7

CMF C19 H22 N2 O3



L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CM 2

CRN 50573-41-6

CMF C8 H11 N O3 S

Absolute stereochemistry. Rotation (-).



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001319876 CAPLUS

DOCUMENT NUMBER: 134:340505

TITLE: Preparation of imidazol-4-ylmethanol as steroid C17-20 lyase inhibitors

INVENTOR(S): Tasaka, Akihito; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yasaka, Masao

PATENT ASSIGNEE(S): Taiho Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 166 pp.

CODEN: PIXX02



DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO. KIND DATE APPLICATION NO. DATE

WO 2001030762 A1 20010503 WO 2000-JP7283 20001019
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU,
CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ,
LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO,
RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GH, KE, LS, MW, HZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MG, NL, PT, SE, BF, BJ,
CG, CI, CM, CO, CR, GW, MR, NE, SN, TD, TG
EP 1222174 A1 20020717 EP 2000-969903 20001019
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL
JP 2002080458 A2 20020319 JP 2000-327022 20001020
PRIORITY APPLN. INFO.: JP 1999-301556 A 19991022
JP 2000-189728 A 20000620
WO 2000-JP7283 W 20001019OTHER SOURCE(S): MARPAT 134:340505
GI


AB Title compds. (I) [wherein R = H or a protecting group; R1 = (cyclo)alkyl]

14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 R3 and R5 = H, acyl, halo, or (un)substituted alkyl, hydroxyl, thio, or amino; R4 = (un)substituted aryl, heterocyclic, or carbamoyl; or R3 and R4 form a 5- or 6-membered O-contg. ring; or R4 and R5 form a 5- or 6-membered O-contg. ring; R6 = (halo)alkyl; n = 0-3; or salt thereof, which have an inhibitory activity on steroid C17-20 lyase, were prep'd. For example, Me 6-(1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-2-naphthoate (prepn. given) was deesterified using NaOH and MeOH in THF, converted to the amide using MeNH₂, and deprotected using pyridinium chloride to give the imidazolyl naphthalenemethanol II. II inhibited steroid C17-20 lyase with IC₅₀ of 6.1 nM and showed inhibitory activity on testosterone biosynthesis (testosterone concn. of groups of rats receiving the imidazolyl naphthalenemethanol II was 1.5% after 14 days of prevention and treatment of breast cancer or prostate cancer (no data).
 IT 247173-89-79, 1-(6,7-dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 247173-54-28, N-(1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)naphthalen-2-ylacetamide
 RL: PUR (Purification or recovery); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); (intermediate); prepn. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 247173-41-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-,(6,7-dimethoxy-2-naphthalenyl)-.alpha.-,(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-54-2 CAPLUS
 CN Acetamide, N-[6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl]- (9CI) (CA INDEX NAME)




IT 247173-85-99, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 247174-15-99, 1-(6-tetra-
 propylamino)-247174-38-89, 1-(6-Bromonaphthalen-2-yl)-1-(1-trityl-1H-imidazol-4-yl)methanol 337522-37-78, 1-(6-((Diphenylmethylene)amino)naphthalen-2-yl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 247174-41-09, N-[6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]naphthalen-2-yl]acetamide 336103-03-89, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthalenemethide 337520-93-19, 337520-95-39
 337520-97-59, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthonitrile 337520-99-79 337521-03-69,


14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate (prepn. given) was deesterified using NaOH and MeOH in THF, converted to the amide using MeNH₂, and deprotected using pyridinium chloride to give the imidazolyl naphthalenemethanol II. II inhibited steroid C17-20 lyase with IC₅₀ of 6.1 nM and showed inhibitory activity on testosterone biosynthesis (testosterone concn. of groups of rats receiving the imidazolyl naphthalenemethanol II was 1.5% after 14 days of prevention and treatment of breast cancer or prostate cancer (no data).
 IT 337521-09-29, 337521-12-79,
 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthoate 337521-14-99 337521-16-19, Methyl 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-1-methyl-2-naphthoate 337521-18-39, 1-(6-tert-Butylmethylsilyloxy)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl 337521-20-49, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthoate 337521-24-19 337521-26-39
 337521-28-59, 1-(6-tert-Butylmethylsilyloxy-2-naphthyl)(1-trityl-1H-imidazol-4-yl)methanol 337521-31-09, (6-tert-Butylmethylsilyloxy-2-naphthyl)(1-trityl-1H-imidazol-4-yl)sethanone 337521-33-29, (6-Hydroxy-2-naphthyl)(1-trityl-1H-imidazol-4-yl)methane 337521-35-49 337521-37-69, Methyl 6-[1-trityl-1H-imidazol-4-yl]carbonyl-2-naphthoate 337521-39-89
 , N-Methyl-6-[1-(1-trityl-1H-imidazol-4-yl)carbonyl]-2-naphthamide 337521-47-59, 6-[1-Hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthoate 337521-53-69
 337521-55-89, Methyl 6-[1-hydroxy-3-methyl-1-(1-trityl-1H-imidazol-4-yl)butyl]-2-naphthoate 337521-57-09, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)butyl]-2-methoxypropyl 337521-58-19 337521-60-59, 2-Hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)butyl]-2-methoxypropyl 337521-61-69
 , 2-Hydroxy-6-[1-hydroxy-2-sethyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-62-72, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-63-89
 337521-64-91, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-1-naphthamide 337521-67-79
 2-Methyl-1-(6-phenyl-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-69-49, 1-(6-(2-Furyl)-2-naphthyl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-72-99, 2-Methyl-1-(6-(2-thienyl)-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-75-21 337521-76-39, 2-Methyl-1-(6-(1H-1,2,3-triazol-4-yl)-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-78-59, 2-Methyl-1-(6-(1H-1,2,3-tetrazol-5-yl)-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-80-99
 1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337521-82-19, 2-Methyl-1-(6-(1,3-oxazol-5-yl)-2-naphthyl)-1-(1-trityl-1H-imidazol-4-yl)-1-propano 337521-83-29, Methyl 6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337521-85-49, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-87-59
 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methoxy-2-naphthoate 337521-92-39, (1H-furan-2,1-b)furan-7-yl(1-trityl-1H-imidazol-4-yl)methanol 337521-92-49, (1H-furan-2,1-b)furan-7-yl(1-trityl-1H-imidazol-4-yl)ketone 337521-94-59, (1H-imidazol-4-yl)(1H-furan-2,1-b)furan-7-yl)ketone 337521-99-09, (1H-imidazol-4-yl)(1H-furan-2,1-b)furan-7-yl)ketone 337522-01-09, 2,3-Dihydro-1H-imidazol-4-yl)methanol 337522-07-39, (2,3-Dihydro-1H-imidazol-4-yl)chromen-8-yl(1-trityl-1H-imidazol-4-yl)ketone 337522-08-49, (2,3-Dihydro-1H-imidazol-4-yl)chromen-8-yl(1H-imidazol-4-yl)ketone 337522-16-49, (1,2-Dihydropyran-2,1-b)furan-7-yl(1-trityl-1H-imidazol-4-yl)methanol 337522-18-69, (1,2-Dihydropyran-2,1-b)furan-7-yl(1-trityl-1H-imidazol-4-yl)ketone

14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 337522-19-79, 1-(2-Diaryldimethylsilyloxy-2,1-b)furan-7-yl(1H-imidazol-4-yl)propyl 337522-20-69, 1-(2,3-Diaryldimethylsilyloxy-2,1-b)furan-6-yl(1H-imidazol-4-yl)propyl 337522-27-78, 1-(2,3-Diaryldimethylsilyloxy-2,1-b)furan-6-yl(1H-imidazol-4-yl)propyl 337522-39-89, 1-(6-(Bromonaphthalen-2-yl)-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 337522-39-69, 1-(6-((Diphenylmethylene)amino)naphthalen-2-yl)-2-methyl-1-(1-trityl-1H-imidazol-4-yl)-1-propanol 247174-41-09, N-[6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]naphthalen-2-yl]acetamide 336103-03-89, (S)-(-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthalenemethide 337520-93-19, 337520-95-39
 337520-97-59, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthonitrile 337520-99-79 337521-03-69,
 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337522-47-19, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-propyl-2-naphthamide 337522-51-79,
 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-isopropyl-2-naphthamide 337522-55-19, N-Butyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-59-59, N-Cyclopropyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-63-19, N-Cyclobutyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-66-49, N-Ethyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-68-49, N-Cyclopropyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-71-59, N-Cyclobutyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-74-69, N-Ethyl-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(1,3-chiazol-2-yl)-2-naphthamide 337522-78-09, N-Ethoxy-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(1,3-chiazol-2-yl)-2-naphthamide 337522-78-89, 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthoate 337522-81-39, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-2-naphthamide 337522-85-79,
 1-Chloro-6-[1-hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337522-91-59, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,1-Dimethyl-2-naphthamide 337522-96-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N,3-dimethyl-2-naphthamide 337523-01-09,
 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-04-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-07-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-09-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-12-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-15-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-18-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-21-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-24-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-27-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-30-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-33-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-36-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-39-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-42-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-45-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-48-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-51-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-54-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-57-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-60-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-63-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-66-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-69-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-71-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-74-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-77-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-80-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-83-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-86-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-89-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-92-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-95-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-98-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-101-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-104-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-107-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-110-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-113-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-116-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-119-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-122-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-125-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-128-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-131-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-134-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-137-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-140-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-143-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-146-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-149-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-152-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-155-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-158-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-161-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-164-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-167-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-170-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-173-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-176-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-179-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-182-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-185-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-188-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-191-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-194-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-197-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-200-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-203-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-206-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-209-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-212-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-215-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-218-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-221-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-224-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-227-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-230-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-233-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-236-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-239-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-242-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-245-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-248-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-251-09, 6-[1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl]-N-(3-methyl-1,2,3-triazol-4-yl)-2-naphthamide 337523-254-09, 6-[1-Hydroxy-2-methyl-1-(

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 247174-39-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-[(diphenylmethylethylene)amino]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethylethyl)- (9CI) (CA INDEX NAME)




RN 247174-41-0 CAPLUS
 CN Acetamide, N-(6-[(1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 336103-03-8 CAPLUS
 CN 2-Naphthalene-carboxamide, 6-[(15)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337520-93-1 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337520-95-3 CAPLUS
 CN 2-Naphthalene-carbonitrile, 6-[(1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl)- (9CI) (CA INDEX NAME)



RN 337520-97-5 CAPLUS
 CN 2-Naphthalene-carbonitrile, 6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 337520-99-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-[(1,1-dimethylethyl)dimethylsilyloxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-03-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-hydroxy-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-05-8 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 1-chloro-6-[(1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl ester (9CI) (CA INDEX NAME)



RN 337521-07-0 CAPLUS
 CN 2-Naphthalene-carboxylic acid, 1-chloro-6-[(1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-09-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-[(1,1-dimethylethyl)dimethylsilyloxy]-5-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-12-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-5-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-14-9 CAPLUS
 CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-16-1 CAPLUS
 CN 2-Naphthalene-carboxylic acid, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-1-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-18-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-[(1,1-dimethylethyl)dimethylsilyloxy]-7-methyl-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-22-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-7-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-24-1 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-3-methyl-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-26-3 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- methyl ester (9CI) (CA INDEX NAME)




RN 337521-28-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-[(1,1-dimethylethyl)dimethylsilyl]oxy)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-31-0 CAPLUS
CN Methane, [6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-1-(triphenylmethyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337521-47-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-[(1,1-dimethylethyl)dimethylsilyl]oxy)-2-naphthalenyl)-.alpha.-(2-methylpropyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-51-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-53-6 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-3-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)butyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-55-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-3-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)butyl]- methyl ester (9CI) (CA INDEX NAME)




RN 337521-33-2 CAPLUS
CN Methane, (6-hydroxy-2-naphthalenyl)-1-(triphenylmethyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337521-35-4 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-37-6 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-39-8 CAPLUS
CN 2-Naphthalenecarboxamide, N-methyl-6-[(1-(triphenylmethyl)-1H-imidazol-4-yl)carbonyl]- (9CI) (CA INDEX NAME)




RN 337521-47-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-[(1,1-dimethylethyl)dimethylsilyl]oxy)-2-naphthalenyl)-.alpha.-(2-methylpropyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-51-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337521-53-6 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-3-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)butyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-55-8 CAPLUS
CN 2-Naphthalenecarboxylic acid, 6-[1-hydroxy-3-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)butyl]- methyl ester (9CI) (CA INDEX NAME)




RN 337521-57-0 CAPLUS
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)



RN 337521-58-1 CAPLUS
CN 1-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-methoxy-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-60-5 CAPLUS
CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-61-6 CAPLUS
CN 1-Naphthalenecarboxamide, 2-hydroxy-6-[1-hydroxy-2-methyl-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(trifluoromethyl)-1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337521-62-7 CAPLUS
CN 1-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-63-8 CAPLUS
CN Methanesulfonic acid, trifluoro-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-1-(methyloxime)carbonyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 337521-64-9 CAPLUS
CN 1-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-(1-(trifluoromethyl)-1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-67-2 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-phenyl-2-naphthalenyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 337521-69-4 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(6-(2-furanyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 337521-72-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(2-thienyl)-2-naphthalenyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 337521-75-2 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-76-3 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 337521-78-5 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-tetrazol-5-yl)-2-naphthalenyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 337521-80-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-1-(trifluoromethyl)-.alpha.-(6-(1-(trifluoromethyl)-1H-pyrazol-4-yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-82-1 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(5-oxazolyl)-2-naphthalenyl)-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337521-83-2 CAPLUS
CN 2-Naphthalene carboxylic acid, 6-[1-hydroxy-2-methyl-1-(1-(trifluoromethyl)-1H-imidazol-4-yl)propyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 337521-85-4 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-(1-(trifluoromethyl)-1H-imidazol-4-yl)propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-88-7 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-(1-(trifluoromethyl)-1H-imidazol-4-yl)propyl]-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-92-3 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-naphtho(2,1-b)furan-7-yl-1-(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 337521-93-4 CAPLUS
CN Methanone, naphtho[2,1-b]furan-7-yl[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 337521-94-5 CAPLUS
CN Methanone, 1H-imidazol-4-ylnaphtho[2,1-b]furan-7-yl- (9CI) (CA INDEX NAME)




RN 337521-99-0 CAPLUS
CN Methanone, 1H-imidazol-4-ylnaphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)




RN 337522-06-2 CAPLUS
CN 1H-Imidazol-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337522-07-3 CAPLUS
CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 337522-08-4 CAPLUS
CN Methanone, (2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-16-4 CAPLUS
CN 1H-Imidazol-4-methanol, .alpha.-(1,2-dihydronaphtho[2,1-b]furan-7-yl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337522-18-6 CAPLUS
CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 337522-19-7 CAPLUS
CN Methanone, (1,2-dihydronaphtho[2,1-b]furan-7-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-26-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,3-d]furan-6-yl)- (9CI) (CA INDEX NAME)




RN 337522-27-7 CAPLUS
CN Methanone, (2,3-dihydronaphtho[2,3-d]furan-6-yl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 337522-28-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydronaphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-29-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-[(phenylmethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 337522-43-7 CAPLUS
CN 2-Naphthalene carboxamide, N-ethyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)



RN 337522-47-1 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 337522-51-7 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-55-1 CAPLUS
CN 2-Naphthalene carboxamide, N-butyl-6-[1-hydroxy-2-methyl-1-[(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-59-5 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)



RN 337522-63-1 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cyclobutyl-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)




RN 337522-66-4 CAPLUS
 CN 2-Naphthalenecarboxamide, N-(cyclopentylmethyl)-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)




RN 337522-68-6 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cyclopentyl-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-81-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1-methyl- (9CI) (CA INDEX NAME)



RN 337522-85-7 CAPLUS
 CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1-N-methyl- (9CI) (CA INDEX NAME)




RN 337522-91-5 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337522-96-0 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1-N,N-dimethyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337522-70-0 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cyclohexyl-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)



RN 337522-73-3 CAPLUS
 CN 2-Naphthalenecarboxamide, N-cycloheptyl-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)




RN 337522-75-5 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)




RN 337522-78-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 1-chloro-6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 337523-01-0 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1-methyl- (9CI) (CA INDEX NAME)



RN 337523-04-3 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1,N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-08-7 CAPLUS
 CN Pyrrolidine, 1-[(6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]carbonyl- (9CI) (CA INDEX NAME)




RN 337523-14-5 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-2-methyl-1-(1-triphenylmethyl)-1H-imidazol-4-yl]propyl-1-N-2-thiazolyl- (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPIUS COPYRIGHT 2003 ACS (Continued)




RN 337523-18-9 CAPIUS
 CN 2-Naphthalene carboxamide, N-ethoxy-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl] (9CI) (CA INDEX NAME)



RN 337523-22-5 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-(1-methylethoxy) (9CI) (CA INDEX NAME)




RN 337523-25-8 CAPIUS
 CN 2-Naphthalene carboxamide, N-(2-hydroxyethyl)-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl] (9CI) (CA INDEX NAME)




RN 337523-29-2 CAPIUS
 CN Glycine, N-[(6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPIUS COPYRIGHT 2003 ACS (Continued)


RN 337523-43-0 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-2-propenyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-45-2 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-49-6 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[cyclopropylhydroxy[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-53-2 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]-3-butenyl]-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPIUS COPYRIGHT 2003 ACS (Continued)




RN 337523-34-9 CAPIUS
 CN L-Alanine, N-[(6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-34-2 CAPIUS
 CN D-Alanine, N-[(6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]-2-naphthalenyl)carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-41-8 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]ethyl]-N-methyl- (9CI) (CA INDEX NAME)




L4 ANSWER 8 OF 33 CAPIUS COPYRIGHT 2003 ACS (Continued)


RN 337523-55-4 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-59-8 CAPIUS
 CN 2-Naphthalene carboxamide, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]-N-methyl- (9CI) (CA INDEX NAME)



RN 337523-69-0 CAPIUS
 CN 2-Naphthalene carboxonitrile, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)




RN 337523-71-4 CAPIUS
 CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl]-.alpha.-[1-methylethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-73-6 CAPIUS
 CN 1H-Imidazole-4-methanol, .alpha.-[5-chloro-6-(1H-1,2,3-triazol-4-yl)-2-


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-78-1 CAPLUS
 CN 2-Naphthalenecarboxaldehyde, 1-chloro-6-[1-hydroxy-2-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]propyl]- (9CI) (CA INDEX NAME)



RN 337523-80-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-(5-oxazolyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-84-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-88-3 CAPLUS

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337524-02-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337534-08-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-, (-)-, compd. with (4R)-2-hydroxy-5,5-dimethyl-1-phenyl-1,3,2-dioxaphosphorinane 2-oxide (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-55-7
 CMF C19 H22 N2 O3

Absolute stereochemistry. Rotation (-).




CH 2


CRN 98674-80-7
 CMF C11 H15 O4 P

Absolute stereochemistry. Rotation (-).


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 2-Naphthalenecarbonitrile, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-90-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-[5-(trimethylsilyl)-1H-1,2,3-triazol-4-yl]-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 337523-92-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 337523-96-3 CAPLUS
 CN 2-Naphthalenecarboxaldehyde, 6-[1-hydroxy-3-methyl-1-[1-(triphenylmethyl)-1H-imidazol-4-yl]butyl]- (9CI) (CA INDEX NAME)




RN 337523-98-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2-methylpropyl)-.alpha.-(6-(5-oxazolyl)-

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




IT 337521-96-79, 1-(1H-Imidazol-4-yl)-1-[naphtho[2,3-d][1,3]dioxol-6-yl]-2-methyl-1-propanol 337522-45-99, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl-2-naphthamide 337522-94-89, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl-1-2-naphthamide 337523-27-09, Ethyl [(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoyl)amino]acetate 337523-39-4P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl-2-naphthamide 337523-51-09, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl-2-naphthamide 337523-67-89, 1-[5-Chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol RL: BAC (Biological activity or effector, except adverse); BSI (Biological study, unclassified); RCT (Reactant); SPA (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prep. of imidazol naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)

RN 337521-96-79 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-naphtho[2,3-d]-1,3-dioxol-6-yl- (9CI) (CA INDEX NAME)




RN 337522-45-9 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 337522-94-8 CAPLUS
 CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,3-dimethyl- (9CI) (CA INDEX NAME)

L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 337523-27-0 CAPLUS
CN Glycine, N-[(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl)carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




IT 336102-55-79, (S)-(-)-1-(6,7-Dimethoxy-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 336102-68-29, Methyl 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthoate 336102-70-69, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl-2-naphthamide 336102-73-99, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)propyl]-N-methyl-2-naphthamide 337521-66-19, 1-(1H-imidazol-4-yl)-2-methyl-1-(6-phenyl-2-naphthyl)-1-propanol 337521-68-39, 1-[6-(2-Furyl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337521-70-79, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(2-thienyl)-2-naphthyl]-1-propanol 337521-74-19, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-1,2-triazol-4-yl)-2-naphthyl]-1-propanol 337521-77-49, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-1,2,3,4-tetrazol-5-yl)-2-naphthyl]-1-propanol 337521-78-69, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1H-imidazol-4-yl)-2-naphthyl]-1-propanol 337521-81-09, 1-(1H-imidazol-4-yl)-2-methyl-1-[6-(1,3-oxazol-2-yl)-2-naphthyl]-1-propanol 337521-84-39, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methyl-2-naphthamide 337521-86-59, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-methoxy-2-naphthamide 337521-89-89, 1-(1H-imidazol-4-yl)-1-(naphtho[2,1-b]furan-7-yl)-2-methyl-1-propanol 337521-95-69, 1-(1,2-Dihydropyranophtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-00-69, 1-(2,3-Dihydro-1H-benzof[1]chromen-8-yl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337522-09-59, 1-(2,3-Dihydro-1H-benzof[1]chromen-8-yl)-1-(1H-imidazol-4-yl)ethanol 337522-10-89, 1-(2,3-Dihydro-1H-benzof[1]chromen-8-yl)-1-(1H-imidazol-4-yl)propanol 337522-12-09, 1-(2,3-Dihydropyranophtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-ethanol 337522-21-19, 1-(2,3-Dihydropyranophtho[2,1-b]furan-7-yl)-1-(1H-imidazol-4-yl)-1-propanol 337522-31-39, 337522-33-59, (-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl acetamide 337522-40-49, 337522-41-59, N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]naphthalen-2-yl acetamide 337522-49-39, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropyl-1-(2-naphthyl)-1-propanol 337522-52-99, N-Ethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-57-39, N-Cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-61-99, N-Cyclobutyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-64-29, N-Cyclopentylmethyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-65-79, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-69-79, N-Cyclohexyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-72-29, N-Cycloheptyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-74-49, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337522-77-79, 1-Chloro-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-


RN 337523-27-0 CAPLUS
 CN Glycine, N-[(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl)carbonyl]-, ethyl ester (SCI) (CA INDEX NAME)

EtO-C(=O)-CH₂-NH-C(=O)-C₆H₄-C(OH)(C₂H₅)C₁H₄N=C1=NH

RN 337523-39-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)ethyl]-N-methyl-
(9CI) (CA INDEX NAME)




RN: 337523-51-0 CAPLUS
CN: 2-Naphthalene-carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)butyl]-N-methyl-
(9CI) (CA INDEX NAME)



RN 337523-67-8 CAPLUS
CN 1H-1imidazole-4-methanol, .alpha.-[5-chloro-6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 methylimidazol-1-yl)-2-naphthalenemethanol 337522-78-09 6-[1-(Hydroxy-1-(1H-imidazol-4-yl)-2-naphthalenyl)-1-methyl-2-naphthamide 337522-83-5P
 1-Chloro-6-[1-(Hydroxy-1-(1H-imidazol-4-yl)-2-naphthalenyl)-2-methylpropyl]-N-methyl-2-naphthamide 337522-88-0P 6-[1-(Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-1-N,1-dimethyl-2-naphthamide 337522-99-3P
 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl-2-naphthamide 337523-03-2P 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl-2-naphthamide 337523-06-5P, 1-(1H-Imidazol-4-yl)-2-methyl-1-(6-[1-pyrrolidinylcarbonyl]-2-naphthyl)-1-propanol 337523-11-2P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1,3-thiazol-2-yl)-2-naphthamide 337523-16-7P
 N-Ethoxy-6-[1-(Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthamide 337523-20-3P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-isopropoxy-2-naphthamide 337523-24-7P, N-(2-Hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-32-3P, 337523-36-1P 337523-47-9P
 337523-61-2P, 337523-62-3P, (-)-6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthyl-1-butanol 337523-63-4P
 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-65-6P, (S)-(-)-N-Cyclopentyl-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthamide 337523-76-9P
 1-(5-Chloro-1-(3,1-oxazol-5-yl)-2-naphthyl)-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337523-82-7P, 6-[1-Hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-2-naphthalene 337523-86-1P, 1-(1H-Imidazol-4-yl)-3-methyl-1-(6-[1H,2,3-triazol-4-yl]-2-naphthyl)-1-butanol 337523-94-1P, 1-(1H-Imidazol-4-yl)-3-methyl-1-[6-(1,3-oxazol-5-yl)-2-naphthyl]-1-butanol 337523-99-0P-2P, 1-[6-(4-Dimethyl-1,5-dihydro-1,3-oxazol-2-yl)-2-naphthyl]-1-(1H-imidazol-4-yl)-2-methyl-1-propanol 337524-05-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of imidazolyl naphthalenemethanol steroid C17-20 lyase inhibitors for treatment of breast and prostate cancer)
 33674-55-1 CAPLUS
 1H-Imidazol-4-*alpha*-methanol, *alpha*,-(6,7-dimethoxy-2-naphthalenyl)-*alpha*,-(6-naphthalenyl)-*alpha*,-(6-naphthalenyl-5-*alpha*-furan-1-*alpha*1,6*alpha*-INDXY-NHMS

Absolute stereochemistry. Rotation (-).




RN 336102-68-2 CAPLUS
CN 2-Naphthaleneacrylic acid, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-, methyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 336102-70-6 CAPLUS
CN 2-Naphthalene-carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]-N-methyl- (9CI) (CA INDEX NAME)




RN 336102-73-9 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-




RN 337521-66-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(1-methylethyl)-.alpha.-(6-phenyl-2-




RN 337521-68-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(2-furanyl)-2-naphthalenyl]-.alpha.-[1-methylethyl] - (9CI) (CA INDEX NAME)




RN 337521-70-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(2-thienyl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-74-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-77-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-tetrazol-5-yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-79-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1H-pyrazol-4-yl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-81-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(5-oxazolyl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 337521-84-3 CAPLUS
 CN 2-Naphthalene carboxamide, 6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 337521-86-5 CAPLUS
 CN 2-Naphthalene carboxamide, 6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-methoxy- (9CI) (CA INDEX NAME)




RN 337521-89-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(1H-imidazol-4-yl)-2-naphthalenyl- (9CI) (CA INDEX NAME)




RN 337521-95-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydroneaphtho[2,1-b]furan-7-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-00-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-09-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-10-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(2,3-dihydro-1H-naphtho[2,1-b]pyran-8-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-12-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydroneaphtho[2,1-b]furan-7-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 337522-21-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1,2-dihydroneaphtho[2,1-b]furan-7-yl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337522-31-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6,7-dimethoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)-.(-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 336102-55-7

CMF C19 H22 N2 O3


Absolute stereochemistry. Rotation (-).




14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CH 2
CRN 110-17-8
CNF C4 H4 O4

Double bond geometry as shown.

RN 337522-33-5 CAPLUS
CN Acetamide, N-[6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]-, (-)- (9CI) (CA INDEX NAME)


Rotation (-).

RN 337522-40-4 CAPLUS
CN Acetamide, N-[6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]-, (-)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 337522-33-5
CNF C19 H21 N3 O2

Rotation (-).







CH 2






CRN 110-17-8
CNF C4 H4 O4

Double bond geometry as shown.





14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-41-5 CAPLUS
CN 2-Naphthalene-carboxamide, N-ethyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-49-3 CAPLUS
CN 2-Naphthalene-carboxamide, 6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)RN 337522-53-9 CAPLUS
CN 2-Naphthalene-carboxamide, N-butyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-57-3 CAPLUS
CN 2-Naphthalene-carboxamide, N-cyclopropyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)

14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-61-9 CAPLUS
CN 2-Naphthalene-carboxamide, N-cyclobutyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-64-2 CAPLUS
CN 2-Naphthalene-carboxamide, N-(cyclopropylmethyl)-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-67-5 CAPLUS
CN 2-Naphthalene-carboxamide, N-cyclopentyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-69-7 CAPLUS
CN 2-Naphthalene-carboxamide, N-cyclohexyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)

14 ANSWER 8 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 337522-72-2 CAPLUS
CN 2-Naphthalene-carboxamide, N-cycloheptyl-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-74-4 CAPLUS
CN 2-Naphthalene-carboxamide, 6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-77-7 CAPLUS
CN 2-Naphthalene-carboxamide, 1-chloro-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)- (9CI) (CA INDEX NAME)RN 337522-79-9 CAPLUS
CN 2-Naphthalene-carboxamide, 6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-1-methyl- (9CI) (CA INDEX NAME)RN 337522-83-5 CAPLUS
CN 2-Naphthalene-carboxamide, 1-chloro-6-[(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 337522-88-0 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,1-dimethyl- (9CI) (CA INDEX NAME)




RN 337522-99-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 337523-03-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 337523-06-5 CAPLUS
CN Pyrrolidine, 1-[(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenylcarbonyl)-2-




RN 337523-32-7 CAPLUS
CN L-Alanine, N-[(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 337523-36-1 CAPLUS
CN D-Alanine, N-[(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenylcarbonyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 337523-47-4 CAPLUS
CN 2-Naphthalenecarboxamide, 6-(cyclopropylhydroxy-1H-imidazol-4-ylmethyl)-N-methyl- (9CI) (CA INDEX NAME)




RN 337523-61-2 CAPLUS




RN 337523-11-2 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-2-thiazolyl- (9CI) (CA INDEX NAME)



RN 337523-16-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethoxy-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 337523-20-3 CAPLUS
CN 2-Naphthalenecarboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-N-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 337523-24-7 CAPLUS
CN 2-Naphthalenecarboxamide, N-(2-hydroxyethyl)-6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-63-4 CAPLUS
CN 2-Naphthalenecarboxamide, N-ethyl-6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 337523-65-6 CAPLUS
CN 2-Naphthalenecarboxamide, N-cyclopropyl-6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 337523-76-9 CAPLUS
CN 1H-imidazole-4-methanol, .alpha.-[5-chloro-6-(5-oxazolyl)-2-naphthalenyl]-.alpha.-[(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337523-82-7 CAPLUS
CN 2-Naphthalene carboxamide, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-3-methylbutyl]- (9CI) (CA INDEX NAME)




RN 337523-86-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(2-methylpropyl).alpha.-(6-(1H-1,2,3-triazol-4-yl)-2-naphthalenyl)}- (9CI) (CA INDEX NAME)



RN 337523-94-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(2-methylpropyl).alpha.-(6-(5-oxazolyl)-2-naphthalenyl)}- (9CI) (CA INDEX NAME)



RN 337524-00-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(4,5-dihydro-4,4-dimethyl-2-oxazolyl)-2-naphthalenyl}.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 337524-05-7 CAPLUS
CN 2-Naphthalene carboxamide, 6-[(1S)-1-hydroxy-1-(1H-imidazol-4-yl)propyl]-N-(2S)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CH 1

CRN 336103-03-8
CMF C18 H19 N3 O2


Absolute stereochemistry. Rotation (-).




CH 2

CRN 110-17-8
CMF C4 H4 O4


Double bond geometry as shown.



IT 247174-44-3, 6-[(1-Hydroxy-2-methyl-1-(1-trityl-1H-imidazol-4-yl)propyl)-2-naphthaldehyde (9CI) (CA INDEX NAME)
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; prepn. of imidazolyl naphthalenemethanol steroid C17-20
lysase inhibitors for treatment of breast and prostate cancer)
247174-44-3 CAPLUS
RN 2-Naphthalene carboxaldehyde, 6-[(1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl)- (9CI) (CA INDEX NAME)



RN 337522-97-1 CAPLUS
CN 2-Naphthalene carboxylic acid, 6-[(1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl)-3-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001-85068 CAPLUS
DOCUMENT NUMBER: 134-260881
TITLE: Potential Antidepressants Displayed Combined .alpha.2-Adrenoceptor Antagonist and Monoamine Uptake Inhibitor Properties

AUTHOR(S): Cordi, Alain; Baume-Bestel, Isabelle; Persigand, Michel; Laroche, Jean-Michel; Newman-Tancredi, Adrian; Audinot, Valerie; Millan, Mark J.

CORPORATE SOURCE: Institut de Recherches Servier, Suresnes, F-92150, Fr.
SOURCE: Journal of Medicinal Chemistry (2001), 44(5), 787-805

CODEN: JMCAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Classical antidepressants are thought to act by raising monoamine (serotonin and norepinephrine) levels in the brain. This action is generally accomplished either by inhibition of monoamine metab. (MAO inhibitors) or by blockade of monoamine uptake (tricyclic antidepressants and selective serotonin or norepinephrine reuptake inhibitors). However, all such agents suffer from a time lag (3-6 wk) before robust clin. efficacy can be demonstrated. This delay may reflect inhibitory actions of norepinephrine on presynaptic .alpha.2A-adrenergic auto. heteroreceptors which gradually down-regulate with prolonged exposure. Blockade of serotonin and norepinephrine by an antagonist endowed with monoamine uptake inhibition properties could lead to new antidepressants with greater efficacy and a shorter time lag. In the literature, only two mol. have been described with such a pharmacol. profile. Of these, naphazoline was chosen as a point of departure for the design of 4(5)-[(3,4-dihydro-2-naphthalenyl)methyl]-4,5-dihydroimidazole, which displayed the desired profile: .alpha.2A-adrenoceptor antagonist properties and serotonin/norepinephrine uptake inhibition. From this original mol., a series of derivs. was designed and synthesized, encompassing substituted as well as rigid analogs. Structure-activity relationships permitted the selection of (4(5)-[(5-fluorindan-2-yl)methyl]-4,5-dihydroimidazole) as a development candidate.

IT 331992-77-9P 331992-78-0P
RL: RCT (Reactant); SPF (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and structure-activity relations of potential antidepressants displaying combined .alpha.2A-adrenoceptor antagonist and monoamine uptake inhibitory activities)


RN 331992-77-9 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-[(1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



RN 331992-78-0 CAPLUS
CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-[(1-(triphenylmethyl)-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 9 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 37 THERE ARE 37 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 2001:12424 CAPLUS
 DOCUMENT NUMBER: 134:86245
 TITLE: Preparation of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors.
 INVENTOR(S): Chow, Kenz Gil, Daniel W.; Burke, James A.; Harcourt, Dale A.; Garst, Michael E.; Wheeler, Larry A.; Munk, Stephen A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 145 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001000586	A1	20010104	WO 2000-US15795	20000608
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CH, GA, GN, GW, ML, MR, NE, SN, TD, TG		EP 2001-933699	20000608	
EP 1104407	A1	20010606	EP 2001-933699	20000608
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2002156076	A1	20021024	US 2001-948001	20010906
PRIORITY APPLN. INFO.:			US 1999-329752 A	19990610
			US 1997-985347 B2	19971204
			US 1998-205597 B2	19981204
			WO 2000-US15795 W	20000608
			US 2000-679919 A1	20001005

OTHER SOURCE(S): MARPAT 134:86245

GI



AB Title compds. [I; dotted lines = optional double bonds; R = H, alkyl; X = S, CHR1; R1 = H, alkyl, null; Y = O, N, S, [C(R1)n]ly, CH:CH, Y1CH2; y = 1-3; n = 1, 2; R2 = H, alkyl, halo, OH, alkoxy, alkenyl, acyl, alkynyl, etc.; R3, R4 = H, alkyl, halo, alkenyl, acyl, alkyanyl, etc.; R3R4 = atoms to form (unsatd.) (heterocyclic) ring], were prep'd. Thus, 1-(dimethylsulfamoyl)imidazole in THF at -78.degree. was treated with BuLi and tert-butyldimethylsilyl chloride followed by warming to room temp., stirring overnight, cooled to -20.degree., and treatment with BuLi and stirring overnight, cooled to -20.degree., and treatment with BuLi and


L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 3-thiophene-carboxaldehyde followed by warming to room temp. and stirring overnight to give 2-(tert-butylidimethylsilyl)-5-(hydroxythiophen-2-ylmethyl)imidazole-1-sulfonic acid dimethylamide. This was treated sequentially with Bu4NF, Et3SiH/CF3CO2H/CH2Cl2, and aq. HCl to give 4(S)-thiophen-3-ylmethyl-1H-imidazole. Tested I as eyedrops at 0.03-1% reduced intraocular pressure in cynomolgus monkeys by 12.4-33% and showed no adverse activity.

IT 157058-47-4#

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses); (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-55-4P 226570-89-4P 226571-02-4P

226571-05-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)


RN 157058-55-4 CAPLUS

CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)





RN 226570-89-4 CAPLUS

CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl



L4 ANSWER 10 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 226571-02-4 CAPLUS
 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)RN 226571-05-7 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)IT 157058-44-1 157058-52-1 226571-13-7
 226571-14-8 226571-25-1 226571-26-2
 226571-35-3 226571-36-4 226571-37-5


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses); (prepn. of imidazoles as selective agonists at .alpha.2b or .alpha.2b/.alpha.2c adrenergic receptors)

RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)


RN 157058-52-1 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)RN 226571-13-7 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-26-2 CAPLUS
 CN 1(2H)-Naphthalene, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226571-36-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




• HCl

RN 226571-37-5 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl- (9CI) (CA INDEX NAME)



IT 226571-57-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of imidazoles as selective agonists at α .2b or α .2b/ α .2c adrenergic receptors)
 RN 226571-57-9 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000-911226 CAPLUS

DOCUMENT NUMBER: 134:56671

TITLE: Process for the preparation of 4-alkoxyimidazoles derivatives and 1-(2-naphthyl)-1-(1H-imidazol-4-yl)alkanol derivatives

INVENTOR(S): Kawakami, Jun-ichi

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXD2





DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078727	A1	20001228	W 2000-JP4036	20000621
W: AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, RO, RU, SG, SI, TR, TW, TW, UA, UG, US, VE, VZ, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TR, TW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GV, ML, MR, NE, SN, TD, TG	A2	20010313	JP 2000-191081	20000621
JP 2001064264	A2	20010313	EP 2000-940770	20000621
EP 1193258	A1	20020403	EP 2000-940770	20000621
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO	PRIORITY APPLN. INFO.:	JP 1999-175070	A 19990622	
		WO 2000-JP4036	W 20000621	
OTHER SOURCE(S): CASREACT 134:56671; MARPAT 134:56671	GI			



AB An industrially advantageous process for the prepn. of compds. of general formula (I) wherein the ring A is an optionally substituted imidazole ring; R is an optionally substituted hydrocarbon group or a heterocyclic


L4 ANSWER 11 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 group; and R1, R2, R3, R4, R5, R6, and R7 are each hydrogen, optionally substituted hydrocarbyl, OH, SH, NH2, acyl, halogeno, or the like) comprises addn. reaction of 4-cyanoimidazole (II; the ring A is same as above) with R-M1 (R is same as above; M1 = alkali metal, Mg-Y1; Y1 = halo) to give 4-acylimidazole (III; R and ring A are same as above), followed by addn. reaction of III with naphthalene alkali metals (IV; R1 - R7 are same as above; M2 is alkali metal, Mg-Y2; Y2 is halo). This process is reduced in the no. of steps, attains a high yield, and dispenses with the use of a heavy metal compd. The compds. I exhibit a steroid C17-C20 lyase inhibitory activity (no data). Thus, a soln. of 42.7 g 4-cyanoimidazole in 500 mL THF was added dropwise to a 1.1 M soln. of isopropylmagnesium bromide in THF (1.4 L) over a period of 30 min, stirred at 15-25 degree, treated dropwise with 10L aq. H2SO4, stirred for 30 min, neutralized to pH 8 with 30 aq. NaOH, and extd. with EtOAc (300 L times 2) to give 82% 1-(1H-imidazol-4-yl)-2-methyl-1-propanone (IV). 2-bromo-6-methoxynaphthalene (15 g) was added dropwise to a mixt. of 0.5% NaBH4 in THF at 50 degree, and stirred at 15-25 degree, for 1.5 h, followed by adding dropwise a soln. of 1 g V in THF, and the resulting mixt. was stirred at 15-25 degree, for 8 h to give, after workup, 84% 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methylpropanol.

IT 247173-05-39

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of 4-alkanylimidazole derivs. and .alpha.- (2-naphthyl)-.alpha.- (1H-imidazolyl)alkanol derivs. by addn. reaction of cyanoimidazoles with alkylmagnesium bromides followed by naphthylmagnesium bromide)

RN 247173-05-3 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.- (6-methoxy-2-naphthalenyl)-.alpha.- (1-methylethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1999-691084 CAPLUS
 DOCUMENT NUMBER: 131:299449
 TITLE: Preparation of azolylmethylnaphthalenes and related compounds as steroid C17,20-lyase inhibitors.
 INVENTOR(S): Tasaka, Akihiro; Ojida, Akio; Kaku, Tomohiro; Kusaka, Masami; Yamaka, Masao
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 131 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 1999-3P2143	A1	19991028	WO 1999-3P2143	19990422
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GV, ML, MR, NE, SN, TD, TG				
CA 2328973	AA	19991028	CA 1999-2328973	19990422
JP 2000007658	A2	20000111	JP 1999-114398	19990422
EP 1073640	A1	1073640	EP 1999-917102	19990422
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			JP 1998-113801	A 19980423
OTHER SOURCE(S): MARPAT 131:299449			WO 1999-3P2143	W 19990422

GI



I

AB Title compds. (I; A1 = (substituted) imidazolyl, thiazolyl, oxazolyl, pyridyl; R11 = H, (substituted) hydrocarbyl, monocyclic heterocycl; R21 = H, (substituted) alkyl; R3-R6 = H, (substituted) hydrocarbyl, OH, SH, amino, acyl, halo; R21 = (substituted) alkyl) are steroid C17,20-lyase inhibitors, etc. Thus, 2-bromo-6-methoxynaphthalene in THF at 70 degrees was treated with BuLi and then with 4-formyl-1-trityl-1H-imidazole to give (6-methoxynaphthalen-2-yl)(1-trityl)-1H-imidazol-4-yl)methanol. The product was refluxed with MnO2 in CHCl3 to give the ketone, which was detriplylated with HCO2H in THF to give (1H-imidazol-4-yl)(6-methoxynaphthalen-2-yl) ketone. The latter in THF at

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 -10 degree. was treated with Me2CBr in THF to give 1-(1H-imidazol-4-yl)-1-(6-methoxynaphthalen-2-yl)-2-methyl-1-propanol. This inhibited rat steroid C17,20-lyase with IC50 = 33 nM. I drug formulations are given.

IT 247173-05-39 247173-06-4P 247173-07-5P

247173-09-7P 247173-11-1P 247173-12-2P

247173-13-3P 247173-14-4P 247173-17-7P

247173-18-8P 247173-19-9P 247173-20-2P

247173-21-3P 247173-22-4P 247173-23-5P

247173-24-6P 247173-25-0P 247173-26-8P

247173-27-9P 247173-28-0P 247173-29-1P

247173-30-4P 247173-31-5P 247173-32-6P

247173-33-7P 247173-34-8P 247173-35-9P

247173-36-0P 247173-37-1P 247173-38-2P

247173-39-3P 247173-40-6P 247173-41-7P

247173-42-8P 247173-43-9P 247173-44-0P

247173-45-1P 247173-46-2P 247173-47-3P

247173-48-4P 247173-49-5P 247173-50-6P

247173-51-9P 247173-52-0P 247173-53-1P

247173-54-2P 247173-55-3P 247173-56-4P

247173-57-5P 247173-58-6P 247173-59-7P

247173-60-0P 247173-61-1P 247173-62-2P


247173-63-3P 247173-64-4P 247173-65-5P

247173-66-6P 247173-68-8P 247173-69-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (I) (prepn. of azolylmethylnaphthalenes and related compds. as steroid C17,20-lyase inhibitors)


RN 247173-05-39 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.- (6-methoxy-2-naphthalenyl)-.alpha.- (1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-06-4 CAPLUS


CN 1H-Imidazole-4-methanol, .alpha.- (6-methoxy-2-naphthalenyl)-.alpha.-methyl- (9CI) (CA INDEX NAME)




RN 247173-07-5 CAPLUS

CN 1H-Imidazole-4-methanol, .alpha.- (6-methoxy-2-naphthalenyl)-.alpha.- (trifluoromethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

CN 1 247173-09-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-cyclopropyl-.alpha.- (6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)


CRN

247173-08-6
 CMF C18 H19 N2 O2


CN 2

CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.

CN 247173-11-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.- (1,1-dimethylethyl)-.alpha.- (6-methoxy-2-naphthalenyl)-, (2E)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CN 1


CRN 247173-10-0
 CMF C19 H22 N2 O2

CN 2


CRN 110-17-8
 CMF C4 H4 O4

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Double bond geometry as shown.




RN 247173-12-2 CAPLUS
 CN 3-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-13-3 CAPLUS
 CN 4-Pyridinemethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-14-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl- (9CI) (CA INDEX NAME)




RN 247173-17-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-fluoro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


Double bond geometry as shown.




RN 247173-18-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-ethyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)



RN 247173-19-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 247173-20-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-propyl- (9CI) (CA INDEX NAME)




RN 247173-21-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-cyclopentyl-.alpha.-(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-22-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-hydroxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-23-5 CAPLUS
 CN 1H-Imidazole-1,4-dimethanol, .alpha.4-(6-hydroxy-2-naphthalenyl)-.alpha.4-(1-methylethyl)-, .alpha.1-acetate (9CI) (CA INDEX NAME)




RN 247173-24-6 CAPLUS
 CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 247173-25-7 CAPLUS
 CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]- (9CI) (CA INDEX NAME)




RN 247173-26-8 CAPLUS

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 1H-Imidazole, 4-[methoxy(6-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)


RN 247173-27-9 CAPLUS
 CN 1H-Imidazole, 4-[(6-methoxy-2-naphthalenyl) (1-methylethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 247173-28-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-29-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-chloro-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-30-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(5-[1-[(1,1-dimethylethyl)dimethylsilyl]oxy]ethyl)-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-31-5 CAPLUS
 CN 1,6-Naphthalenedimethanol, .alpha.-6-1H-imidazol-4-yl-2-methoxy-.alpha.-1-methyl-.alpha.-6-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-32-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[1-methylethyl]-.alpha.-[6-(phenyloxymethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-33-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethyl)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-34-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethyl)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-35-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl)oxy]methyl ester (9CI) (CA INDEX NAME)




RN 247173-36-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-(1-methylethoxy)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-37-1 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[1-methylethyl]-.alpha.-[6-propoxy-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-38-2 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 247173-39-3 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-(2-methoxystyloxy)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-40-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-ethoxy-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-41-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6,7-dimethoxy-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-42-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-methyl-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-43-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[5-(6-dimethoxy-2-naphthalenyl)-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)



RN 247173-44-0 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-hydroxy-7-methoxy-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-45-1 CAPLUS
 CN 1,6-Naphthalenedimethanol, .alpha.-6-1H-imidazol-4-yl-2-methoxy-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)




RN 247173-46-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(methoxymethyl)-2-naphthalenyl]-.alpha.-[1-methylethyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-47-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 247173-48-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-ethenyl-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-49-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(5-bromo-6-methoxy-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-50-8 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-(fluoromethoxy)-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-55-3 CAPLUS
CN Urea, N'-(6-[1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl]-2-naphthalenyl)-N,N-dimethyl- (9CI) (CA INDEX NAME)




RN 247173-56-4 CAPLUS
CN Urea, N-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]-N'-methyl- (9CI) (CA INDEX NAME)




RN 247173-57-5 CAPLUS
CN Methanesulfonamide, N-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247173-58-6 CAPLUS
CN 2,6-Naphthalenedimethanol, .alpha.-1H-imidazol-4-yl-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-51-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-5,7-dimethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-52-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-bromo-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-53-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-amino-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-54-2 CAPLUS
CN Acetamide, N-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
RN 247173-59-7 CAPLUS
CN Ethanone, 1-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


RN 247173-60-0 CAPLUS
CN 1-Propanone, 1-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 247173-61-1 CAPLUS
CN 1-Propanone, 1-[6-(1-hydroxy-1-(1H-imidazol-4-yl)-2-methylpropyl)-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)




RN 247173-62-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(6-ethyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-63-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-methyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-64-4 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethynyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-65-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(methylthio)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-66-6 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-1-methyl-2-naphthalenyl)-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247173-68-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-71-3 CAPLUS
 CN Methanone, (6-methoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)



RN 247173-72-4 CAPLUS
 CN Methanone, 1H-imidazol-4-yl(6-methoxy-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247173-73-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-methyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-74-6 CAPLUS
 CN 3-Pyridinemethanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-(triphenylmethyl)-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247173-69-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1-methylethyl)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




IT 247174-67-0
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (prepn. of azolylmethylnaphthalenes and related compds. as steroid
 C17,20-lyase inhibitors)
 RN 247174-67-0 CAPLUS
 CN Methanone, (5-fluoro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




IT 247173-70-2P 247173-71-3P 247173-72-4P
 247173-73-5P 247173-74-6P 247173-75-7P
 247173-76-8P 247173-81-5P 247173-82-6P
 247173-83-7P 247173-85-9P 247173-86-0P
 247173-88-2P 247173-89-3P 247173-90-6P
 247173-92-8P 247173-93-9P 247173-94-0P
 247173-95-1P 247173-98-4P 247173-99-5P
 247174-00-1P 247174-01-2P 247174-03-4P
 247174-04-5P 247174-05-6P 247174-06-7P
 247174-07-8P 247174-08-9P 247174-09-0P
 247174-10-3P 247174-11-4P 247174-12-5P
 247174-16-9P 247174-17-0P 247174-24-9P
 247174-25-0P 247174-26-1P 247174-29-4P
 247174-31-8P 247174-35-2P 247174-36-3P
 247174-38-5P 247174-39-6P 247174-40-9P
 247174-41-0P 247174-42-1P 247174-43-2P
 247174-44-3P 247174-45-4P 247174-46-5P
 247174-47-6P 247174-48-7P 247174-50-1P
 247174-51-2P 247174-52-3P 247174-54-5P
 247174-63-6P 247174-64-7P 247174-65-8P
 247174-66-9P 247174-69-2P 247174-72-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of azolylmethylnaphthalenes and related compds. as steroid
 C17,20-lyase inhibitors)
 RN 247173-70-2 CAPLUS


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247173-75-7 CAPLUS
 CN 4-Pyridinemethanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-(1-(4-pyridinemethyl)-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)




RN 247173-76-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-methoxy-2-naphthalenyl)-.alpha.-phenyl-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-81-5 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-(phenylmethoxy)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-82-6 CAPLUS
 CN Methanone, [6-(phenylmethoxy)-2-naphthalenyl][1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 247173-83-7 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[1-(methyl ethyl)-.alpha.-(6-(phenylmethoxy)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-85-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-hydroxy-2-naphthalenyl]-.alpha.-[1-(methyl ethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-86-0 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-(acetyloxy)-2-naphthalenyl]-.alpha.-[1-(methyl ethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-88-2 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)ethyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-89-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl-2-naphthalenyl- (9CI) (CA INDEX NAME)




RN 247173-90-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-2-naphthalenyl]-.alpha.-[1-(methyl ethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-92-8 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)-2-methylpropyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-93-9 CAPLUS
CN 1H-Imidazole, 4-[1-methoxy-1-(6-methoxy-2-naphthalenyl)methyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-94-0 CAPLUS
CN 1H-Imidazole, 4-[1-(6-methoxy-2-naphthalenyl)(1-methylethoxy)methyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-95-1 CAPLUS
CN Methanone, (5-chloro-6-methoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 247173-98-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[5-[1-[(1,1-dimethylethyl)dimethylsilyloxy]ethyl]-6-methoxy-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247173-99-5 CAPLUS
CN Methanone, [5-{1-[(1,1-dimethylethyl)dimethylsilyloxy]ethyl}-6-methoxy-2-naphthalenyl]-1-(triphenylmethyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)




RN 247174-00-1 CAPLUS
CN Methanone, [5-{1-[(1,1-dimethylethyl)dimethylsilyloxy]ethyl}-6-methoxy-2-naphthalenyl]-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)



RN 247174-01-2 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-(phenylmethoxy)-2-naphthalenyl)- (9CI) (CA INDEX NAME)




RN 247174-03-4 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-[6-methoxy-5-(1-methylethyl)-2-naphthalenyl]-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-04-5 CAPLUS
CN Methanone, (6-methoxy-5-(1-methylethyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 (triphenylmethyl)-1H-imidazol-4-yl) - (9CI) (CA INDEX NAME)




RN 247174-05-6 CAPLUS
 CN Methanone, 1H-imidazol-4-yl[6-methoxy-5-(1-methylethenyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-06-7 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, [(6-[1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-naphthalenyl)oxy]methyl ester (9CI) (CA INDEX NAME)




RN 247174-07-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-(1-methylethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RN 247174-08-9 CAPLUS
 CN Propanoic acid, 2,2-dimethyl-, 6-[1-hydroxy-2-methyl-1-(1-(triphenylmethyl)-1H-imidazol-4-yl)propyl]-2-naphthalenyl ester (9CI) (CA INDEX NAME)




RN 247174-09-0 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-(2-methoxyethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-10-3 CAPLUS
 CN Methanone, (6-ethoxy-2-naphthalenyl)[1-(triphenylmethyl)-1H-imidazol-4-yl]- (9CI) (CA INDEX NAME)




RN 247174-11-4 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-ethoxy-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-12-5 CAPLUS
 CN Methanone, (6,7-dimethoxy-2-naphthalenyl)-1H-imidazol-4-yl- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-16-9 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-17-0 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-[(1,1-dimethylethyl)dimethylsilyl]oxy]-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247174-24-9 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)




RN 247174-25-0 CAPLUS
 CN Methanone, 1H-imidazol-4-yl[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]- (9CI) (CA INDEX NAME)


L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 247174-26-1 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[7-methoxy-6-(phenylmethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 247174-29-4 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[5-ethenyl-6-methoxy-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)







RN 247174-31-8 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-(fluoromethoxy)-2-naphthalenyl]-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)








RN 247174-35-2 CAPLUS
 CN 1H-imidazole-4-methanol, .alpha.-[6-methoxy-5,7-dimethyl-2-naphthalenyl]- (9CI) (CA INDEX NAME)







L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 247174-36-3 CAPLUS
CN Methanone, 1H-imidazol-4-yl(6-methoxy-5,7-dimethyl-2-naphthalenyl)- (9CI) (CA INDEX NAME)RN 247174-38-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(6-bromo-2-naphthalenyl)-.alpha.-{(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)RN 247174-39-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{6-[(diphenylmethyle)amino]-2-naphthalenyl]-.alpha.-{(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)RN 247174-40-9 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(6-amino-2-naphthalenyl)-.alpha.-{(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)






RN 247174-41-0 CAPLUS

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
CN Acetamide, N-[6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)RN 247174-42-1 CAPLUS
CN Urea, N-[6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)RN 247174-43-2 CAPLUS
CN Methanesulfonamide, N-[6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)RN 247174-44-3 CAPLUS
CN 2-Naphthaleneacraldehyde, 6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)- (9CI) (CA INDEX NAME)RN 247174-45-4 CAPLUS
CN 2,6-Naphthalenedimethanol, .alpha.-{(1-methylethyl)-.alpha.-{(1-(triphenylmethyl)-1H-imidazol-4-yl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-46-5 CAPLUS
CN Ethanone, 1-[6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]- (9CI) (CA INDEX NAME)RN 247174-47-6 CAPLUS
CN 1-Propanone, 1-[(6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)RN 247174-48-7 CAPLUS
CN 1-Propanone, 1-[(6-[(1-hydroxy-2-methyl-1-[(triphenylmethyl)-1H-imidazol-4-yl]propyl)-2-naphthalenyl]-2-methyl- (9CI) (CA INDEX NAME)RN 247174-50-1 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(6-ethenyl-2-naphthalenyl)-.alpha.-{(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-51-2 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(6-ethyl-2-naphthalenyl)-.alpha.-{(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)RN 247174-52-3 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(1-methylethyl)-.alpha.-{(6-methyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)RN 247174-54-5 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(6-ethynyl-2-naphthalenyl)-.alpha.-{(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)RN 247174-63-6 CAPLUS
CN 1H-Imidazole-4-methanol, .alpha.-{(1-methylethyl)-.alpha.-{(6-(2-propenyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


RN 247174-64-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propyl-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-65-8 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-(1-methylethyl)-2-naphthalenyl)-.alpha.-(1-methylethyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)




RN 247174-66-9 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-(1-methylethyl)-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-69-2 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(6-ethoxy-2-naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)



RN 247174-72-7 CAPLUS
 CN 1H-Imidazole-4-methanol, .alpha.-(1-methylethyl)-.alpha.-(6-propoxy-2-

L4 ANSWER 12 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 naphthalenyl)-1-(triphenylmethyl)- (9CI) (CA INDEX NAME)

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:175530 CAPLUS
 DOCUMENT NUMBER: 131:19013
 TITLE: Preparation of .alpha.2B and .alpha.2C adrenoceptor agonists
 INVENTOR(S): Cho, Sung Gil, Daniel W., Burke, James A., Harcourt, Dale A., Garst, Michael E., Wheeler, Larry A., Munk, Stephen A.
 PATENT ASSIGNEE(S): Allergan Sales, Inc., USA
 SOURCE: PCT Int. Appl., 121 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9928300	A1	19990610	WO 1998-US25669	19981203
W: AU, AM, AT, AU, GB, DE, BE, BG, BY, CA, CH, CN, CU, CZ, DE, DK, ES, FI, GB, GE, GH, HK, HR, IL, IS, JP, IE, KG, NO, NZ, PL, PT, RU, SD, SE, SG, SI, SK, SI, TR, TR, TT, UA, UG, UZ, VN, YU, ZW	AM, AZ, BY, KG, KZ, MD, RU, TJ, TR, TT, UA, UG, UZ, VN, YU, ZW	19981203	19981203	
RM: GH, GM, KE, LS, MW, SD, SZ, UG, ZW	AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, MU, MR, NE, SN, TD, TG	19981203	19981203	
CA 2312334	AA	19990610	CA 1998-2312334	19981203
AU 9918025	A1	19990616	AU 1999-18025	19981203
AU 744798	B2	20002307		
EP 1036065	A1	20000920	EP 1999-962883	19981203
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI	BR 9813381	A	20001003	19981203
BR 9813381	A	20001003	BR 1998-13381	19981203
JP 200152452	T2	20011204	JP 2000-523194	19981203
NO 200002773	A	20000802	NO 2000-2773	20000530
US 2002156076	A1	20021204	US 2000-348001	20000506

PRIORITY APPLN. INFO.: US 1997-91526 A 19971204

US 1998-US25669 W 19980603

US 1998-205597 B2 19981204

US 1999-329752 B3 19990610

US 2000-679919 A1 20000105


OTHER SOURCE(S): MARPAT 131:19013

AB Title compds. of diverse structural type were prep'd. Thus, 7-methoxy-1-tetralone was condensed with 1-dimethylsulfamoyl-2-tert-butylidimethylsilyl-5-imidazolylcarboxaldehyde (prep'n. given) and the product converted in 3 steps to 4-(5-(7-methoxy-1,2,3,4-tetrahydronaphth-2-ylmethyl)-1H-imidazole. Data for biol. activity of title compds. were given.


IT 137058-44-1P 157058-47-4P 157058-52-1P
 137058-53-4P 226570-89-4P 226571-02-4P
 226571-03-7P 226571-13-7P 226571-14-8P
 226571-24-2P 226571-26-2P 226571-35-3P
 226571-36-4P 226571-37-5P 226571-43-3P
 226571-55-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); TRU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses); (prep'n. of .alpha.2B and .alpha.2C adrenoceptor agonists)


RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 INDEX NAME)


RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 226570-89-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-monohydrochloride (9CI) (CA INDEX NAME)




● HCl

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 226571-02-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-
 (9CI) (CA INDEX NAME)




RN 226571-05-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)




RN 226571-13-7 CAPLUS
 CN 1H-Imidazole, 4-[(2S)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-14-8 CAPLUS
 CN 1H-Imidazole, 4-[(2R)-1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 226571-25-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4-methyl-2-naphthalenyl)methyl]-
 (9CI) (CA INDEX NAME)


L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 226571-26-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-4-methyl-
 (9CI) (CA INDEX NAME)



RN 226571-35-3 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-4,4-dimethyl-2-naphthalenyl)methyl]-
 (9CI) (CA INDEX NAME)




RN 226571-36-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methyl-2-naphthalenyl)methyl]-
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-37-5 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methyl-
 (9CI) (CA INDEX NAME)

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



RN 226571-43-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4,5,6,7,8-hexahydro-2-(1H-imidazol-4-ylmethyl)-
 monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 226571-55-7 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4,5,6,7,8-octahydro-2-naphthalenyl)methyl]-
 (2E)-2-butenedioate (2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 226571-05-7

CMF C14 H20 N2



CM 2

CRN 110-17-8

CMF C4 H4 O4


Double bond geometry as shown.



IT 226571-57-9
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of alpha.2B and .alpha.2C adrenoceptor agonists)

RN 226571-57-9 CAPLUS
 CN 1-Naphthalenol, 1,2,3,4-tetrahydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy-

L4 ANSWER 13 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1999:244636 CAPLUS
 DOCUMENT NUMBER: 130:252360
 TITLE: Preparation of dihydronaphthalene compounds
 INVENTOR(S): Hartmann, Rolf Wolfgang; Wachall, Bertil; Yoshihama, Makoto; Nakashiki, Masamichi; Nomoto, Shin; Ikeda, Yoshikazu
 PATENT ASSIGNEE(S): Yukijirushi Nyugyo Kabushiki Kaisha, Japan
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9918075	A1	19990415	WO 1998-JP4426	19981001
W: AU, CA, CN, FI, HU, IL, JP, KR, MX, NO, NZ, RU, US				
RM: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9808954	A	19990412	ZA 1998-8954	19981001
AU 9892810	A1	19990427	AU 1998-92810	19981001
AU 743405	B2	20020124		
EP 1028110	A1	20000816	EP 1998-94556	19981001
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
FI 200000207	A	2000201	FI 2000-207	20000201
NO 200001289	A	2000310	NO 2000-1289	20000310
US 2002032211	A1	20020314	US 2001-866179	20010525
PRIORITY APPLN. INFO.:			JP 1997-284263	A 19971002
			WO 1998-JP4426	W 19981001
			US 1999-424126	B1 19991117

OTHER SOURCE(S): MARPAT 130:252360
 GI




AB Dihydronaphthalene compds. I (R1 = H, OH, alkyl, alkoxy, R2 = alkyl, aralkyl, Ph; R3 = alkyl, Ph, pyridyl, imidazolyl), useful as 17, alpha-hydroxylase/C17-20-lyase inhibitors, thromboxane A2 synthesis inhibitors, and aromatase inhibitors, were prepd. I (R1 = H, R2 = Me, R3 = 3-pyridyl) showed 17, alpha-hydroxylase/C17-20-lyase and aromatase inhibitor activity.


IT 157058-45-29 157058-46-39 157058-47-4P
 221651-52-18 221651-54-39 221651-56-5P
 221651-61-28 221651-64-5P

RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. of dihydronaphthalenes)


L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 ACCESSION NUMBER: 157058-45-2 CAPLUS
 DOCUMENT NUMBER: 1(2H)-Naphthalene, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalene, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalene, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 221651-52-1 CAPLUS
 CN 1(2H)-Naphthalene, 5-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 221651-54-3 CAPLUS
 CN 1(2H)-Naphthalene, 6-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)


L4 ANSWER 14 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 221651-56-5 CAPLUS
 CN 1(2H)-Naphthalene, 7-ethoxy-3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)



RN 221651-61-2 CAPLUS
 CN 1(2H)-Naphthalene, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-propoxy- (9CI) (CA INDEX NAME)



RN 221651-64-5 CAPLUS
 CN 1(2H)-Naphthalene, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-(2-methylpropoxy)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 157058-54-217 CAPLUS
 DOCUMENT NUMBER: 121929262
 TITLE: Preparation and biological activity of imidazopyridoindole and imidazopyridobenzothiophene combinatorial libraries
 INVENTOR(S): Ostresh, John M.
 PATENT ASSIGNEE(S): Traga Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9834112	A1	19980806	WO 1997-US22286	19971205
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, DO, DZ, EC, FI, GE, HK, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SZ, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
BE, CH, DE, DK, ES, FI, FR, GR, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5856107	A	19991015	US 1997-794364	19970204
AU 9853740	A1	19980825	AU 1998-53740	19971205
PRIORITY APPLN. INFO.:			US 1997-794364	19970204
			WO 1997-US22286	19971205

OTHER SOURCE(S): MARPAT 129:149262
 GI




AB The invention provides a rapid approach for combinatorial synthesis and screening of libraries of imidazopyridoindole and imidazopyridobenzothiophene I (R1 = H, halo, (un)protected OH, amino, (un)protected carboxy; R2 = H, (un)substituted C1-10 alkyl, (un)substituted Ph, (un)substituted C7-16 phenylalkyl, (un)substituted C3-7 cycloalkyl, (un)substituted naphthyl), in the form of pyridines or pyridobenzothiophenes, each with an adjacent R3 = (un)substituted C1-10 alkyl, (un)substituted C2-10 alkene, (un)substituted C3-7 cycloalkyl, (un)substituted Ph, (un)substituted C7-16 phenylalkyl, (un)substituted naphthyl, (un)substituted heterocycle; X = N, S; Y = H, Me). The present invention further provides methods of prepn. the libraries and the individual compds. made by the combinatorial synthesis. Reactivity ratios for amidation of 85 carboxylic acids to resin-bound dipeptide derivs. are also given, along with reactivity ratios for solid-phase peptide coupling of 25 N-protected amino acids. Thus, 121 sublibraries I, prepd. by


L4 ANSWER 15 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 systematically varying R1 (and X and Y), R2, and R3 were prep'd. via solid-phase peptide coupling of a tryptophan or (benzothiienyl)alanine deriv. (variables R1, X, and Y) to a benzhydrylamine resin, coupling of another amino acid residue (variable R2), coupling of a carboxylic acid residue (variable R3), POC13-induced ring closure, and HF resin cleavage. All 121 prep'd. sublibraries were tested for antimicrobial activity and μ -opioid receptor binding.

IT 210982-44-8DP, combinatorial library derivs. 210983-86-1DP, combinatorial library derivs.
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses) (prep. and biol. activity of imidazopyridoindole and imidazopyridobenzothiophene combinatorial libraries)

RN 210982-44-8 CAPLUS
 CN 5H-Imidazo[1',5':1,2]pyrido[3,4-b]indole-5-carboxamide, 6,11-dihydro-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)



RN 210983-86-1 CAPLUS
 CN [1]Benzothieno[2,3-c]imidazo[1,5-a]pyridine-5-carboxamide, 5,6-dihydro-1-(2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 ACESSION NUMBER: 1996:358249 CAPLUS
 DOCUMENT NUMBER: 125:75343
 TITLE: Synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of P450 arom, P450 17 and P450 Tm2
 AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber, Dorothea; Wachter, Gerald A.; Gruen, Gertrud L.; Sergejew, Tom F.
 CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ. Saarlandes, Saarbruecken, D-66041, Germany
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996), 32(5), 251-261
 CODEN: ARPHAS; ISSN: 0365-6233
 PUBLISHER: VCH
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH₃ substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-space between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 arom (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 Tm2 (citrated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 4C (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone, ACTH stimulated rat adrenal tissue). In vivo, selected compds. were tested in Sprague-Dawley rats regarding P 450 Tm2 inhibition (redu. of plasma testosterone concn., androstenedione concn., redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 arom and/or P 450 17 were found: 7-OCH₃-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH₃-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 arom in vitro known so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH₃ deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 Tm2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 Tm2, whereas 7-OCH₃-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH₃-2-imidazol-1-yl-3,4-dihydronaphthalene both, show strong inhibition of P 450 arom and P 450 17. Stereoselective activities are observed regarding the other steroidogenic P 450 enzymes as well as corticosterone formation. The compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concn. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 arom fadrozole. The compds. show activity in the aforementioned in vivo tests.
 IT 157058-44-1P 157058-45-2P 157058-46-3P
 157058-47-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PREP (Preparation); USES (Uses)

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-44-1 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)



RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




IT 157058-52-1P 157058-53-2P 157058-55-4P
 178880-06-3P

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PREP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIO (Biological study); PREP (Preparation); USES (Uses)
 (synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-52-1 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS
 CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanediolate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 157058-54-3
 CMF C15 H18 N2 O

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CH 2


CRN 144-62-7
CHF C2 H2 O4

L4 ANSWER 17 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:97011 CAPLUS
 DOCUMENT NUMBER: 124:260928
 TITLE: Novel nonprostanoid prostacyclin (PGI2) mimetics with heterocyclic moiety
 AUTHOR(S): Nagao, Yuuki; Takahashi, Kanji; Torisu, Kazuhiko; Kondo, Kigen; Hamanaka, Nobuyuki
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
 SOURCE: Heterocycles (1996), 42(2), 517-23
 PUBLISHER: Japan Society of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal Article
 LANGUAGE: English
 AB Structural modification of [(6-[2-((diphenylmethoxy)imino)pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl)oxy]acetic acid [i.e., (2-(2-benzhydrylonyl)iminopentyl)-1,2,3,4-tetrahydro-5-naphthalenyl]acetic acid], previously identified as a PGI2 agonist without a PG skeleton, was examined. Such analogs were for example, [(6-[3-(diphenylmethyl)-1,2,4-oxadiazol-5-yl]methyl)-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid or [(6-[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl)-5,6,7,8-tetrahydro-1-naphthalenyl]acetic acid. Conversion of the oxime moiety in [(6-[2-((diphenylmethoxy)imino)pentyl]-5,6,7,8-tetrahydro-1-naphthalenyl)oxy]acetic acid to a pyrazole led to [(6-[4-(diphenylmethyl)-1H-pyrazol-1-yl]methyl)-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]acetic acid [i.e., (2-(4-benzhydrylpyrazolyl)methyl)-1,2,3,4-tetrahydro-5-naphthalenyl]acetic acid] which strongly inhibited ADP-induced aggregation of human platelets in vitro.

IT 150559-28-8
 RL: RCL (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reaction or method)
 (prepn. of [(6-[(phenylmethoxy)imino]alkyl)naphthalenyl]oxy)acetate analogs as nonprostanoid prostacyclin mimetics)

RN 150559-29-8 CAPLUS

CN Acetic acid, [(6-[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl)-5,6,7,8-tetrahydro-1-naphthalenyl]oxy] - (9CI) (CA INDEX NAME)



L4 ANSWER 18 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESION NUMBER: 1995:827732 CAPLUS

DOCUMENT NUMBER: 124:202093

TITLE: Molecular design of novel PGI2 agonists without PG skeleton. IV. [Erratum to document cited in CA123:198689]

AUTHOR(S): Hananaka, N.; Takahashi, K.; Nagao, Y.; Torisu, K.; Tokumoto, H.; Kondo, K.
 CORPORATE SOURCE: Minase Res. Inst., Ono Pharmaceutical Co., Ltd., Osaka, 618, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(18), 2179
 CODEN: BMCLB8; ISSN: 0960-894X

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The errors were not reflected in the abstr. or the index entries.

IT 150559-29-8

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (PGI2 agonist activity of (Erratum))

RN 150559-29-8 CAPLUS

CN Acetic acid, [(6-[2-(diphenylmethyl)-1H-imidazol-4-yl]methyl)-5,6,7,8-tetrahydro-1-naphthalenyl]oxy] - (9CI) (CA INDEX NAME)



HO2C-CH2-O

L4 ANSWER 19 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESION NUMBER: 1995:612212 CAPLUS

DOCUMENT NUMBER: 123:198691

TITLE: Medetomidine analogs as α -adrenergic agonists
 AUTHOR(S): Amemiya, Yoshiya; Hsu, Fulian; Shams, Gamali; Feller, Dennis R.; Venkataraman, B. V.; Patil, Popat N.; Miller, Duane D.

CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA

SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 403-10
 CODEN: EJPSSZ; ISSN: 0301-5068

PUBLISHER: National Information and Documentation Centre

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 123:198691


AB Recently, it has been reported that medetomidine is a new 4-substituted imidazole analog possessing selective and potent α -adrenergic properties. It has been shown that it mediates blood pressure, heart rate and respiration. At the present time is sedative and hypotensive effects seem to be manifest in the same dose range. We have initiated a program to see if it is possible to sep. these activities with analogs of medetomidine. The initial studies have been directed at procedures for the conversion of the imidazolines, a common structure of α -adrenergic drugs, to the corresponding imidazoles. It was found that 2-substituted and 2,4-disubstituted imidazolines can easily be converted into imidazoles using 10% Pd/C in refluxing toluene, while in some instances there are some difficulties with the conversion of 4-substituted imidazolines to the imidazoles. The synthesis of 1- or 2-(2- or 4-imidazolylmethyl)naphthalene analogs of medetomidine are also described.

IT 137967-88-5P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of 4-substituted imidazoles)

RN 137967-88-5 CAPLUS

CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:612198 CAPLUS
 DOCUMENT NUMBER: 123:111932
 TITLE: Synthesis and α -adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs of α - and β -naphthalene
 AUTHOR(S): Ameniya, Yoshiya; Venkataraman, Burrab V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl
 CORPORATE SOURCE: College Pharmacy, Ohio State University, Columbus, OH, 43210, USA
 SOURCE: Egyptian Journal of Pharmaceutical Sciences (1994), 35(1-6), 91-112
 CODEN: EJPSSZ ISSN: 0301-5068
 PUBLISHER: National Information and Documentation Centre
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB Seven analogs of medetomidine and naphazoline were synthesized and evaluated for their α - (aorta) and α -2- (platelet) activities. The analogs were composed of 2- and 4-substituted imidazoles and imidazolines attached through a methylene bridge to either an α - or β -naphthalene ring system. In general the α -naphthalene analogs were found to be the most potent inhibitors of platelet aggregation. α -Naphthalene analogs were partial agonists while the β -naphthalene analogs were antagonists in α . α -adrenergic system (aorta).
 IT 137967-82-9 166034-65-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); PREP (Preparation); RACT (synthesis and adrenergic activities of medetomidine and naphazoline analogs)
 RN 137967-82-9 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 166034-65-7 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]-, ethanediolate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 137967-88-5
 CMF C15 H14 N2

L4 ANSWER 21 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:598392 CAPLUS
 DOCUMENT NUMBER: 123:198689
 TITLE: Molecular design of novel PG12 agonists without PG skeleton. IV
 AUTHOR(S): Hamanaka, Nobuyuki; Takahashi, Kazuji; Nagao, Yuuki; Torisu, Kazuhiko; Tomimoto, Hidekado; Kondo, Kigen
 CORPORATE SOURCE: Himeji Res. Inst., Otsu Pharmaceutical Co., Ltd., Osaka, 619, Japan
 SOURCE: Bioorganic & Medicinal Chemistry Letters (1995), 5(10), 1083-6
 CODEN: BMCLB8 ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




I

AB The synthesis and biol. evaluation of a novel series of di- or tetrahydronaphthalen-5-oxyacetic acid derivs. with a 4-benzhydrylpyrazolyl group is described. Among these compds., I has been identified as a highly potent PG12 agonist with an exceptionally long *in vivo* duration of action.
 IT 150559-29-8
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
 (PG12 agonist activity of)
 RN 150559-29-8 CAPLUS
 CN Acetic acid, [(E)-[(2-(diphenylmethyl)-1H-imidazol-4-yl)methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy]- (9CI) (CA INDEX NAME)

HO₂C-CH₂-O-


L4 ANSWER 20 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)



CH 2



CRN 144-62-7
 CMF C2 H2 N4

IT 137967-88-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (synthesis and adrenergic activities of medetomidine and naphazoline analogs)
 RN 137967-88-5 CAPLUS
 CN 1H-imidazole, 4-[1-(2-naphthalenyl)ethyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1995:513524 CAPLUS
 DOCUMENT NUMBER: 122:265375
 TITLE: Preparation of (cyanobenzyl)azole derivatives as aromatase inhibitors
 INVENTOR(S): Shibata, Tomoyuki; Sugimura, Yukio; Tanzawa, Kazuhiko; Takahashi, Masaaki; Kobayashi, Tomoyo; Mitsuhashi, Yoshihiro
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 94 pp.
 CODEN: PIXKD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9408970	A1	19940428	WO 1993-JP1509	19931020
W, AU, CA, CZ, FI, HU, IL, NO, NZ, RU, US				
RU, AT, BE, CH, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9352855	A1	19940509	AU 1993-52855	19931020
JP 06263742	A2	19940920	JP 1993-261438	19931020
PRIORITY APPLN. INFO.:				
JP 1992-283177				19921021
WO 1993-JP1509				19931020

OTHER SOURCE(S): MARPAT 122:265379
 GI


AB The title compds. (I; R1 = imidazolyl, triazolyl or tetrazolyl each of which may be substituted with Me and/or Et; R2 = naphthyl, phenanthryl or anthryl each of which may be substituted by substituent(s) selected from Cl-4 alkyl, Cl-4 alkoxy, Cl-6 acyloxy, arom. acyloxy, OH, trialkyl, Cl-4 acylamino, alkoxyalkoxy, alkoxyacyloxy, and trialkylsilyloxy; R3 = H, Me, cyano), useful for the treatment of breast cancer, are prep'd. Thus, 2-bromo-6-methoxynaphthalene was treated with BuLi in hexane and THF at

L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 -78 degrees, followed reaction with a soln. of p-cyanobenzaldehyde in THF at -78 degrees, gave p-cyano- α -(6-methoxynaphthalen-2-yl)benzyl alc. which was stirred in SOCl_2 in CH_2Cl_2 at room temp, for 1 h to give p-cyano- α -(6-methoxynaphthalen-2-yl)benzyl chloride. The latter chloride was dissolved in MeCN and refluxed with imidazole overnight to give, after silica gel chromatog. and acidification with HCl, title compd. (II.HCl) which in vitro showed IC_{50} of 3.7 μM against aromatase. Hard capsule, tablet, injection and suspension formulations contg. (p-cyanobenzyl)tetraol deriv. (III.HCl) were described.


IT 162573-42-4P 162573-46-8P 162573-58-2P
 RL: BAN (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of (cyanobenzyl)azole deriv. as aromatase inhibitor and antiestrogen agent for breast cancer)

RN 162573-42-4 CAPLUS

CN Benzonitrile, 4-(1H-imidazol-4-yl-2-naphthalenylmethyl)- (9CI) (CA INDEX NAME)




RN 162573-46-8 CAPLUS
 CN Benzonitrile, 4-(1H-imidazol-4-yl-9-phenanthrenylmethyl)- (9CI) (CA INDEX NAME)



RN 162573-58-2 CAPLUS
 CN Benzonitrile, 4-(1H-imidazol-4-yl-2-naphthalenylmethyl)-, monohydrochloride (9CI) (CA INDEX NAME)

L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994-534112 CAPLUS
 DOCUMENT NUMBER: 121:134112
 TITLE: Preparation of imidazolylmethylenetetralones and analogs as aromatase inhibitors
 INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton
 PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan
 SOURCE: PCT Int. Appl., 29 pp
 DOCUMENT TYPE: Patent
 CODEN: PIXXD2
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940114	WO 1993-JP1433	19931006
W: AU, BE, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.:			JP 1992-267130 A	19921006
JP 1992-267130			WO 1993-JP1433 W	19931006
OTHER SOURCE(S):	MARPAT	121:134112		
GI				



AB The title compds. I (R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxycarbonyl) when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, 2 represents hydrogen and the broken line represents an arbitrary bond; n represents an integer of 0 or 1) are prep'd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H_2SO_4 was heated for 20 h at 80-90 degrees, to give, after workup, (8)-2-(4-imidazolylmethylene)-1-tetralone (II). II in vitro IC₅₀ of 0.260 μM against aromatase.

157058-44-19 157058-45-29 157058-46-3P

157058-47-4P 157058-52-19 157058-53-2P


157058-54-3P 157058-55-4P

RL: BAN (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of, as aromatase inhibitor)

RN 157058-44-1 CAPLUS


CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 22 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




● HCl


L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




RN 157058-45-2 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)






RN 157058-47-4 CAPLUS
 CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



RN 157058-52-1 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-53-2 CAPLUS
 CN 1H-imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-

L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
(9CI) (CA INDEX NAME)RN 157058-54-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl] -
(9CI) (CA INDEX NAME)RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl] -
(9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS
ACCESSION NUMBER: 1993:671157 CAPLUS
DOCUMENT NUMBER: 119:271157
TITLE: Fused benzeneoxycylic acid derivative PG12 receptor agonists
INVENTOR(S): Hamanaka, Nobuyuki; Takahashi, Kanji; Tokumoto, Hidekado
PATENT ASSIGNEE(S): One Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 110 pp.
CODEN: EPXWDW

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 548949	A2	19930630	EP 1992-121898	19921223
EP 548949	A3	19931006		
EP 548949	Bl	19970917		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 05178032	A2	19930720	JP 1991-360502	19911227
JP 07025854	A2	19950127	JP 1992-209587	19920714
US 5461045	A	199501024	US 1992-512999	19920714

CA 2073917	AA	19940116	CA 1992-2073917	19920715
CA 2085844	AA	19930626	CA 1992-2085844	19921218
AT 158282	E	19971015	AT 1992-121898	19921218
ES 2108076	TJ	19932116	ES 1992-121898	19921223

US 5389666	A	199501041	US 1992-512992	19921228
JP 05178037	A2	199306306	JP 1991-360502	19911228
US 5589496	A	19961231	US 1994-334395	19941103

US 5849919	A	19981215	US 1996-722456	19960927
US 5962439	A	19991005	US 1998-168424	19981007

PRIORITY APPLN. INFO.:			JP 1991-360502	19911227
			JP 1992-209587	19920714
			US 1992-997492	19921228
			US 1994-334395	19941103
			US 1996-722456	19960927

OTHER SOURCE(S): MARPAT 119:271157



GI For diagram(s), see printed CA Issue.
AB The title compds. I [A = (un)substituted heterocycl; B = alkylene, alkenylene; ring D = carbocyclic ring; R1 = HO, C1-12 alkox, (un)substituted amino], which demonstrate PG12 receptor agonist activity and are useful in the treatment of thrombosis, arteriosclerosis, ischemic heart disease, gastric ulcer, or hypertension (no data), are prep'd. and I-contg. formulations presented. Thus, pyrazole deriv. II was prep'd. which demonstrated 50% inhibitory concn. against human blood platelet aggregation of 0.01-0.1 μM in human blood-derived platelet-rich plasma. 150558-97-5 158282-29-0

IT RL RCT (Reactant); PACT (Reactant or reagent)
(PG12 receptor agonist activity of)

150558-97-5 CAPLUS

CN Acetic acid, [(5,6,7,8-tetrahydro-6-(1H-imidazol-4-ylmethyl)-1-naphthalenyl]oxy] - (9CI) (CA INDEX NAME)

L4 ANSWER 24 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)

RN 150559-29-8 CAPLUS
CN Acetic acid, [[6-[(2-(diphenylmethyl)-1H-imidazol-4-yl)methyl]-5,6,7,8-tetrahydro-1-naphthalenyl]oxy] - (9CI) (CA INDEX NAME)

L4 ANSWER 25 OF 33 CAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:649949 CAPLUS

DOCUMENT NUMBER: 119:249949

TITLE: Preparation of imidazole derivatives as interleukin 1 inhibitors and anti-phlogistics

INVENTOR(S): Ueno, Yoshihiko; Masuori, Hiroaki; Saji, Kitaro
PATENT ASSIGNEE(S): Sumitomo Pharma, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05155882	A2	19930622	JP 1991-348294	19911203

PRIORITY APPLN. INFO.:			JP 1991-348294	19911203
------------------------	--	--	----------------	----------


OTHER SOURCE(S): MARPAT 119:249949

GI For diagram(s), see printed CA Issue.
AB The title derivs. I [A = lower alkylene; M = arom. hydrocarbon ring, thiophene; D = O, CO, CO(OR), C(=O)R, CH[N(R)2]2, NR5, single bond; R1 = H, halide, R2 = low. alkyl or alkenyl, (un)substituted Ph, (un)substituted cycloalkyl, (un)substituted thiophenyl; R3 = N-contg. heterocycl; R4, R5 = H, lower alkyl; when D is single bond then R2 is lower alkyl] or their acid salts are prep'd. as interleukin 1 inhibitors and anti-phlogistics. A mixt. of 3-(2-fluoro-4-biphenyl)-1-(4-pyridylcarboxy)amino-2-butanone (prep'd. from fluorobiprofen in 4 steps), and NH4Ac was heated at 140-150 degree. for 4 h to give 444-4-(1-(2-fluoro-4-biphenyl)ethyl)-2-(4-pyridyl)imidazole-HCl. I inhibited growth of interleukin 1.

IT 150972-40-0P
RL SPM (Synthetic preparation); PREP (Preparation)
(prep. of, as interleukin 1 inhibitor and anti-phlogistics)


RN 150972-40-0 CAPLUS

CN 2-Naphthalenol, 6-[(2-(4-pyridinyl)-1H-imidazol-4-yl)ethyl]-, dihydrochloride (9CI) (CA INDEX NAME)




●2 HCl

L4 ANSWER 26 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1992:106173 CAPLUS
 DOCUMENT NUMBER: 116:106173
 TITLE: Synthesis and α -adrenergic activities of 2- and 4-substituted imidazoline and imidazole analogs
 AUTHOR(S): Amemiya, Yoshiya; Hong, Seoung S.; Venkataraman, Burrash V.; Patil, Popat N.; Shams, Gamal; Romstedt, Karl; Feller, Dennis R.; Hsu, Fu Lian; Miller, Duane D.
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
 SOURCE: Journal of Medicinal Chemistry (1992), 35(4), 750-5
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Analogs I-III (R = 1-naphthyl, 2-naphthyl; R1 = H, Me) of medetomidine and naphazoline were synthesized and evaluated for their α .1 (aorta) and α .2 (platelet) activities. In general the 1-naphthalene analogs were the most potent inhibitors of epinephrine-induced platelet aggregation. Of the stable isomers, the most potent was I (II, 1-naphthyl imidazoline antagonists in α .1-adrenergic system (aorta). Thus, appropriately substituted naphthalene analogs of medetomidine and naphazoline provide a spectrum of α .1-agonist, α .1-antagonist, and α .2-antagonist activity.
 IT 137967-82-9 137967-88-5
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and adrenergic activity of)
 RN 137967-82-9 CAPLUS
 CN 1H-Imidazole, 4-[(1-(2-naphthalenyl)ethyl)-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 137967-88-5 CAPLUS
 CN 1H-Imidazole, 4-[(1-(2-naphthalenyl)ethyl)- (9CI) (CA INDEX NAME)

L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1992:15364 CAPLUS
 DOCUMENT NUMBER: 116:15364
 TITLE: Structure-activity studies of new imidazolines on adrenoceptors of rat aorta and human platelets
 AUTHOR(S): Venkataraman, B. V.; Shams, G.; Hamada, A.; Amemiya, Y.; Tantishaiyakul, V.; Hsu, F.; Fashempour, J.; Romstedt, K. J.; Miller, D. D. et al.
 CORPORATE SOURCE: Coll. Pharm., Ohio State Univ., Columbus, OH, 43210, USA
 SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1991), 344(4), 454-63
 CODEN: NSAPCC; ISSN: 0028-1298
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




AB Potencies of new aro. substituted fluoro or iodo analogs of catecholimidazolines (I) on functional responses in rat aorta (α .1) and platelets (α .2) were quantified. When compared either on the basis of EC50 or the const. (KA), 5-fluorocatecholimidazoline was as potent as the ref. α .1-adrenoceptor agonist, phenylephrine in the vascular tissue. The max. contraction of aorta produced by the fluoro analog was, however, 17% higher than that of phenylephrine. The time required for 1/2 relaxation of the tissue after 5-fluoro hydroxy imidazoline was at least twice as long as that of the phenylephrine. The catechol moiety as well as fluorine substitution at the crit. 5-position of the aro. ring is essential for higher α .1 adrenoceptor-mediated potency. As compared to the fluoro analogs, the adrenoceptor-mediated potencies of iodo-analogs were relatively weak on vascular tissue. Naphazoline and its analogs were partial agonists on vascular tissue with dissooc. consts. which ranged from 110 to 2600 nmol/L. Imidazole analogs (II, 1-naphthyl or nylad) were generally less potent agonists than the imidazolines by one order of magnitude. The vascular effects of all agonists were competitively blocked by prazosin with KB values which ranged from 0.04 to 0.48 nmol/L. Since the variation in KB values were within normal limits, the action of new imidazolines on rat aorta appears to be mediated mainly by the activation of the α .1-adrenoceptor. Prazosin 10 nmol/L abolished the vascular response of some partial agonists. This indicates a slightly different mode of interaction of agonists with the transduction process. Carbon 4-substituted imidazolines produced little or no α .1 adrenoceptor-mediated intrinsic activity, but competitive receptor blocking potency was comparable to that of phentolamine. Medetomidine was a partial agonist on the rat aorta with a KA of 260 nmol/L. When investigated as a blocker, the KB of medetomidine against phenylephrine was approx. 5600 nmol/L. The variation in the latter value was high. In acetylsalicylic acid-treated human platelets, the α .2-adrenoceptor-mediated aggregatory effect of all fluoro analogs was weak. Iodo or naphazoline analogs did not initiate platelet

L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




L4 ANSWER 27 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)
 aggregation but blocked the aggregation induced by epinephrine. The affinity of naphazoline for the α .2-adrenoceptor was 1100 nmol/L. The IC50 of medetomidine for platelet anti-aggregatory effect was 3300 nmol/L, which compares favorably with other imidazoline type of blockers of platelet aggregations. Sympathomimetic vasoconstrictor actions and platelet aggregation effects of these compds. can be dissoed. Some vasoconstrictors were antiaggregatory. The structure-activity relationships of the two receptor systems, namely rat aorta (α .1) and platelets (α .2), are discussed.
 IT 137967-88-5
 RL: BIOL (Biological study)
 (α .1-adrenoceptors of aorta and human platelets interaction with, structure in relation to)
 RN 137967-88-5 CAPLUS
 CN 1H-Imidazole, 4-[(1-(2-naphthalenyl)ethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1991:623482 CAPLUS
 DOCUMENT NUMBER: 115:223482
 TITLE: Use of 5-HT3 receptor antagonists for treatment of panic disorders, agoraphobia, or obsessive compulsive disorders
 INVENTOR(S): Azcona, Alberto
 PATENT ASSIGNEE(S): Sandoz-Erfindungen Verwaltungsgesellschaft m.b.H., Austria; Sandoz-Patent-G.m.b.H.; Sandoz A.-G.
 SOURCE: PCT Int. Appl., 35 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9012569	A1	19901101	WO 1990-EP540	19900406
V: AU, CA, JP, KR, US				
RU: AT, BE, CH, DE, DK, ES, FR, GB, IT, LU, NL, SE				
CA 2031214	AA	19901022	CA 1990-2031214	19900406
AU 9054158	A1	19901116	AU 1990-54158	19900406
AU 631632	B2	19921203		
EP 422154	A1	199010417	EP 1990-905482	19900406
EP 422154	B1	19931201		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE				
JP 03505881	T2	19911219	JP 1990-505770	19900406
JP 06069963	B4	19940907		
AT 97803	E	19931215	AT 1990-905482	19900406
ES 2061024	T3	19941201	ES 1990-905482	19900406
ZA 9003015	A	19911224	ZA 1990-3015	19900420
US 5530008	A	19960625	US 1994-07413	19901214
PRIORITY APPLN. INFO.:				
GB 1989-9147				19890421
GB 1989-16602				19890720
EP 1990-905482				19900406
WO 1990-EP540				19900406
US 1990-635156				19901219


AB 5-HT3 receptor antagonists are useful in treating panic disorders and/or agoraphobia or obsessive compulsive disorders. Formulations for tablets, i.v. solns. and capsules are presented.
 IT 135716-73-3
 RL: BIOL (Biological study)
 (5-HT3 receptor antagonist)
 RN 135716-73-3 CAPLUS
 CN 1(2H)-Phenanthrenone, 3,4-dihydro-2-[(5-methyl-1H-imidazol-4-yl)methyl]-
 (9CI) (CA INDEX NAME)



L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1990:198377 CAPLUS
 DOCUMENT NUMBER: 112:198377
 TITLE: Preparation and formulation of imidazole derivatives as 5-HT3 receptor antagonists
 INVENTOR(S): North, Peter Charles; Oxford, Alexander William; Coates, Ian Harold
 PATENT ASSIGNEE(S): Glaxo Group Ltd., UK
 SOURCE: Eur. Pat. Appl., 12 pp.
 CODEN: EPXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 336759	A1	19891011	EP 1989-303415	19890406
R: AT, BE, CH, DE, ES, FR, GR, IT, LI, LU, NL, SE				
JP 02049772	A2	19900220	JP 1989-87841	19890406
US 5116984	A	19920526	US 1989-333967	19890406
PRIORITY APPLN. INFO.:				
GB 1988-8085				19880407
GB 1988-8086				19880407

OTHER SOURCE(S): MARPAT 112:198377
 GI




AB Title compds. I (R1, R2 = H, halo, HO, Cl-4 alkoxy, Cl-4 alkyl, Cl-4 alkylthio, R3R4, R3, R4 H, Cl-4 alkyl, R3R4 H) and 5,7-membered ring; A = CH, N in substituted imidazolyl (n = 1-3) and physiol. acceptable salts and solvates thereof, potent and selective antagonists of 5-HT3 receptors and useful, e.g., in treatment of psychotic disorders, anxiety, and nausea and vomiting (no data), are prep'd. 1,2-Dihydro-3-[(5-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl)methylene]-4(3H)-phenanthrenone (prepn given) was dehydrogenated over Pd/C to give I (R1, R2 = H; A = CH; Im = 5-methylimidazol-4-yl; n = 2) which was converted to the maleate. Tablet and injection formulations were given.
 IT 126737-68-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as 5-HT antagonist)
 RN 126737-68-6 CAPLUS
 CN 4(1H)-Phenanthrenone, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-, (2Z)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 126737-65-3
 CMF C19 H18 N2 O

L4 ANSWER 28 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)


L4 ANSWER 29 OF 33 CAPLUS COPYRIGHT 2003 ACS (Continued)




CM 2

CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.




IT 126737-65-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as 5-HT antagonist)
 RN 126737-65-3 CAPLUS
 CN 4(1H)-Phenanthrenone, 2,3-dihydro-3-[(5-methyl-1H-imidazol-4-yl)methyl]-
 (9CI) (CA INDEX NAME)




L4 ANSWER 30 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1990:139033 CAPLUS
 DOCUMENT NUMBER: 112:139033
 TITLE: Preparation of imidazole derivatives as drugs
 INVENTOR(S): Kihara, Noriaki; Tomino, Ikuo; Tan, Hiroaki; Takei, Mitsusachi
 PATENT ASSIGNEE(S): Mitsui Petrochemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.
 CODEN: JNOKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01242571	A2	19890927	JP 1988-65731	19880322
PRIORITY APPLN. INFO.:		JP 1988-65731		19880322
OTHER SOURCE(S):		MARPAT 112:139033		
GI				



L4 ANSWER 32 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1973:515495 CAPLUS
 DOCUMENT NUMBER: 79:115495
 TITLE: Synthesis of small molecule catalysts. Model for the active site of ribonuclease-A
 AUTHOR(S): Algeri, Aldo A.
 CORPORATE SOURCE: Cornell Univ., Ithaca, NY, USA
 SOURCE: (1973) 116 pp. Avail.: Univ. Microfilms, Ann Arbor, Mich., Order No. 73-14,715
 From: Diss. Abstr. Int. B 1973, 33(12) (Pt. 1), 5722
 DOCUMENT TYPE: Dissertation
 LANGUAGE: English
 AB Unavailable
 IT 49738-45-6
 RL: RCT (Reactant); RACT (Reactant or reagent)
 as model for the active site of ribonuclease A)
 RN 49738-45-6 CAPLUS
 CN 1H-imidazole-4-ethanamine, N-[(3-(1H-imidazol-4-yl)methyl)-1-naphthalenyl]methyl-, conjugate diacid (9CI) (CA INDEX NAME)

●2 H⁺

L4 ANSWER 33 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1972:501463 CAPLUS
 DOCUMENT NUMBER: 77:101463
 TITLE: Voges-Proskauer reaction. II. Structure of a pigment from the diacetyl reaction of 1-benzyl-1-methylguanidine
 AUTHOR(S): Nishimura, Tamio; Yamazaki, Chiji; Ueno, Tetsuro; Kitajima, Shinichi; Ishige, Koichi
 CORPORATE SOURCE: Sch. Hyg. Sci., Kitasato Univ., Tokyo, Japan
 SOURCE: Bulletin of the Chemical Society of Japan (1972), 45(6), 1762-5
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 AB A pigment formed by the reaction of 1-benzyl-1-methylguanidine was isolated as reddish purple prisms. The reduced pigment was colorless and rapidly converted back to the original pigment on exposure to the air. On the basis of ir, NMR, and mass spectral evidence, the structures of the pigment and the reduced form were established to be 2-(N-benzyl-N-methylamino)-4-methyl-5-(1-oxo-1,2-dihydro-2-naphthylidenemethyl)imidazole and 5-(1-hydroxy-2-naphthylmethyl)imidazole, resp.
 IT 37842-56-1P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 37842-56-1 CAPLUS
 CN 1-Naphthalenol, 2-[(5-methyl-2-[methyl(phenylmethyl)amino]-1H-imidazol-4-yl)methyl]- (9CI) (CA INDEX NAME)



=> log y		
COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	150.78	299.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-20.83	-20.83

STN INTERNATIONAL LOGOFF AT 07:05:47 ON 03 FEB 2003

L4 ANSWER 16 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1996:358249 CAPLUS
 DOCUMENT NUMBER: 125:75343
 TITLE: Synthesis and evaluation of azole-substituted
 tetrahydronaphthalenes as inhibitors of P450 arom,
 P450 17 and P450 TxA2
 AUTHOR(S): Hartmann, Rolf W.; Frotscher, Martin; Ledergerber,
 Dorothea; Waechter, Gerald A.; Gruen, Gertrud L.;
 Sergejew, Tom F.
 CORPORATE SOURCE: Fachrichtung 12.1 Pharmazeutische Chemie, Univ.
 Saarlandes, Saarbruecken, D-66041, Germany
 SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1996),
 329(5), 251-261
 CODEN: ARP MAS; ISSN: 0365-6233
 PUBLISHER: VCH
 DOCUMENT TYPE: Journal
 LANGUAGE: English


AB In search of potential drugs for the treatment of estrogen- and androgen-dependent cancer as well as the prophylaxis of metastases, tetralones, tetralins, and dihydronaphthalenes bearing of OCH₃ substituent at the benzene nucleus and an imidazol-4-yl, imidazol-1-yl, or 1,2,4-triazol-1-yl substituents in 2-position were synthesized with and without C2-spacer between the rings. The compds. were tested in vitro for inhibition of the three target enzymes P 450 arom (human placental microsomes), P 450 17 (rat testicular microsomes), and P 450 TxA2 (citrated human whole blood). To examine selectivity, some compds. were further tested in vitro for inhibition of P 450 18 (bovine adrenal mitochondrial), P 450 scc (bovine adrenal mitochondrial) and corticoid formation (aldosterone, corticosterone; ACTH stimulated rat adrenal tissue). In vivo, selected compds. were examd. in Sprague Dawley rats regarding P 450 TxA2 inhibition, redn. of plasma testosterone concn., antiuterotropic activity (inhibition of the uterotrophic activity of androstenedione), redn. of plasma estradiol concn. (pregnant mares' serum gonadotropin-primed rats), and mammary tumor inhibiting activity (dimethylbenzanthracene-induced tumor; pre- and postmenopausal model). In the series of imidazol-4-yl compds., which represent new azole inhibitors of steroidogenic P 450 enzymes, strong inhibitors of P 450 arom and/or P 450 17 were found; 7-OCH₃-2-(imidazol-4-ylmethylene)-1-tetralone (I) and 7-OCH₃-2-(imidazol-4-ylmethyl)-tetralin (II) are among the most potent inhibitors of P 450 arom in vitro know so far. I is a selective inhibitor, whereas II shows in addn. strong inhibition of P 450 17. In contrast to II, the 6-OCH₃ deriv. is a selective inhibitor of P 450 17, being 50 times more potent than ketoconazole. Some imidazol-1-yl compds. show a marked inhibition of P 450 TxA2: 2-(imidazol-1-ylmethyl)-1-tetralone is a selective inhibitor of P 450 TxA2, whereas 7-OCH₃-2-(imidazol-1-ylmethyl)-tetralin as well as 2-(imidazol-1-ylmethyl)-tetralin and 7-OCH₃-2-imidazol-1-yl-3,4-dihydronaphthalene addnl. show strong inhibition of P 450 arom and P 450 17. Structure-activity relations are discussed. Regarding the other steroidogenic P 450 enzymes as well as corticosterone formation, the compds. show only slight inhibitory activity. Aldosterone formation, however, is inhibited at low concns. Nevertheless, I and II are more selective, i.e. inhibit aldosterone synthesis less than the well known inhibitor of P 450 arom fadrozole. The compds. show activity in the aforementioned in vivo tests.

IT 157058-44-1P 157058-45-2P 157058-46-3P
 157058-47-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




RN 157058-45-2 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)



RN 157058-47-4 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)



IT 157058-52-1P 157058-53-2P 157058-55-4P


178880-06-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(synthesis and evaluation of azole-substituted tetrahydronaphthalenes as inhibitors of human and lab. animal cytochrome P 450 enzymes in relation to structure and hormone formation and uterotrophic activity and mammary tumor inhibition)


RN 157058-52-1 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 157058-53-2 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)




RN 178880-06-3 CAPLUS

CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-, ethanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1


CRN 157058-54-3

CMF C15 H18 N2 O




CM 2

CRN 144-62-7
CMF C2 H2 O4



L4 ANSWER 23 OF 33 CAPLUS COPYRIGHT 2003 ACS
 ACCESSION NUMBER: 1994:534112 CAPLUS
 DOCUMENT NUMBER: 121:134112
 TITLE: Preparation of imidazolylmethylenetetralones and
 analogs as aromatase inhibitors
 INVENTOR(S): Hartmann, Rolf W.; Wachter, Gerald Anton
 PATENT ASSIGNEE(S): Tokyo Tanabe Co. Ltd., Japan
 SOURCE: PCT Int. Appl., 29 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407866	A1	19940414	WO 1993-JP1433	19931006
W: AU, BB, BG, BR, CA, CZ, FI, HU, KR, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9351184	A1	19940426	AU 1993-51184	19931006
JP 06192233	A2	19940712	JP 1993-250257	19931006
PRIORITY APPLN. INFO.:			JP 1992-267130	A 19921006
			WO 1993-JP1433	W 19931006
OTHER SOURCE(S):	MARPAT 121:134112			
GI				




AB The title compds. I [R represents hydrogen, C1-C4 lower alkoxy, nitro or C1-C4 lower alkoxy carbonyl; when X and Y represent each hydrogen or X and Y are combined together to represent oxygen, Z represents hydrogen and the broken line represents an arbitrary bond; when X represents hydrogen, Y and Z are combined together to represent a single bond; n represents an integer of 0 or 1] are prepd. A mixt. of 1-tetralone and imidazole-4-carbaldehyde in 40% H2SO4 was heated for 20 h at 80-90.degree. to give, after workup, (E)-2-(4-imidazolylmethylene)-1-tetralone (II). II in vitro showed IC50 of 0.260 .mu.M against aromatase.

IT 157058-44-1P 157058-45-2P 157058-46-3P
 157058-47-4P 157058-52-1P 157058-53-2P
 157058-54-3P 157058-55-4P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of, as aromatase inhibitor)


RN 157058-44-1 CAPLUS

CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)- (9CI) (CA INDEX NAME)




P^1 is $\text{O}=\text{O}$
 R^2 & R^3 form unsaturated ring
 $R_6 = \text{H}$
 $S = \text{O}$
 $T = \text{O}$


RN 157058-45-2 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-5-methoxy- (9CI) (CA INDEX NAME)




RN 157058-46-3 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-6-methoxy- (9CI) (CA INDEX NAME)




RN 157058-47-4 CAPLUS
CN 1(2H)-Naphthalenone, 3,4-dihydro-2-(1H-imidazol-4-ylmethyl)-7-methoxy- (9CI) (CA INDEX NAME)




RN 157058-52-1 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-2-naphthalenyl)methyl]- (9CI) (CA INDEX NAME)






RN 157058-53-2 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-5-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 157058-54-3 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-6-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)



RN 157058-55-4 CAPLUS
CN 1H-Imidazole, 4-[(1,2,3,4-tetrahydro-7-methoxy-2-naphthalenyl)methyl]-
(9CI) (CA INDEX NAME)

